

Bangkok Dusit Medical Services Public Company Limited
and its subsidiaries
Report and consolidated financial statements
31 December 2015

Report of independent auditor

To the Shareholders of Bangkok Dusit Medical Services Public Company Limited

I have audited the accompanying consolidated financial statements of Bangkok Dusit Medical Services Public Company Limited and its subsidiaries, which comprise the consolidated statement of financial position as at 31 December 2015, and the related consolidated statements of income, comprehensive income, changes in shareholders' equity and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information, and have also audited the separate financial statements of Bangkok Dusit Medical Services Public Company Limited for the same period.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Thai Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with Thai Standards on Auditing. Those standards require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Opinion

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Bangkok Dusit Medical Services Public Company Limited and its subsidiaries and of Bangkok Dusit Medical Services Public Company Limited as at 31 December 2015, and their financial performance and cash flows for the year then ended, in accordance with Thai Financial Reporting Standards.

Wichart Lokatekrawee
Certified Public Accountant (Thailand) No. 4451

EY Office Limited
Bangkok: 29 February 2016

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position

As at 31 December 2015

(Unit: Baht)

	Note	Consolidated financial statements			Separate financial statements		
		As at	As at	As at	As at	As at	As at
		31 December 2015	31 December 2014	1 January 2014	31 December 2015	31 December 2014	1 January 2014
Assets			(restated)			(restated)	
Current assets							
Cash and cash equivalents	7	5,528,543,111	3,608,367,714	4,077,064,557	3,617,144,329	1,862,514,806	1,756,130,780
Short-term investments	8	28,280,659	1,877,618,065	120,375,963	1,353,034	1,583,291,938	12,978
Trade and other receivables	10, 11, 12	6,484,342,871	5,822,137,258	4,925,321,530	1,470,057,934	1,051,772,413	884,799,028
Short-term loans to related parties	12	-	-	-	1,326,938,930	1,755,709,338	912,718,302
Dividend receivable - a related party	12	-	9,100,000	5,979,333	-	-	-
Inventories	13	1,285,769,345	1,110,813,412	918,672,840	99,357,785	98,629,263	100,923,649
Other current assets		255,432,045	270,021,135	199,511,008	30,944,662	22,939,305	21,580,198
Total current assets		13,582,368,031	12,698,057,584	10,246,925,231	6,545,796,674	6,374,857,063	3,676,164,935
Non-current assets							
Long-term deposit at financial institution		-	-	10,418,441	-	-	-
Restricted financial institution deposits	9	60,707,653	29,525,658	20,683,895	14,000,000	14,000,000	14,000,000
Investments in associated companies	14	15,093,034,805	14,182,876,470	13,051,360,616	9,028,589,568	9,028,589,568	8,984,214,568
Investments in subsidiary companies	15	-	-	-	39,070,482,959	36,557,176,437	27,580,937,134
Other long-term investments	16	1,085,157,043	1,006,683,252	500,695,841	771,950,462	664,246,284	282,378,259
Long-term loans to related parties	12	-	-	-	5,786,370,550	5,341,174,983	5,733,377,121
Investment properties	17	284,767,664	265,450,433	260,698,513	530,237,832	519,109,433	514,357,513
Property, premises and equipment	18	52,949,905,969	46,935,257,816	39,318,087,578	8,070,214,543	7,386,789,781	6,934,566,575
Land not used in operation	19	297,307,543	297,307,543	602,007,543	296,981,200	296,981,200	601,681,200
Goodwill	15	16,932,250,590	15,999,933,687	10,944,814,666	-	-	-
Intangible assets	20	1,036,728,473	861,366,691	654,920,313	385,142,951	310,489,847	291,522,819
Other non-current assets							
Leasehold rights	12, 21	670,176,910	700,374,772	698,017,942	362,422,115	379,561,562	396,459,238
Others	12	342,590,020	392,824,164	240,727,530	26,500,933	46,320,418	22,975,502
Total non-current assets		88,752,626,670	80,671,600,486	66,302,432,878	64,342,893,113	60,544,439,513	51,356,469,929
Total assets		#####	93,369,658,070	76,549,358,109	70,888,689,787	66,919,296,576	55,032,634,864

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position (continued)

As at 31 December 2015

(Unit: Baht)

		Consolidated financial statements			Separate financial statements		
		As at	As at	As at	As at	As at	As at
	Note	31 December 2015	31 December 2014	1 January 2014	31 December 2015	31 December 2014	1 January 2014
Liabilities and shareholders' equity			(restated)			(restated)	
Current liabilities							
Bank overdrafts and short-term loans from financial institutions	22	75,859,716	21,850,446	18,941,531	-	-	-
Trade and other payables	12, 23	4,934,750,901	4,388,736,560	3,987,827,551	1,288,882,537	927,757,614	986,902,792
Current portion of long-term loans from financial institutions	24	1,708,223,631	1,592,367,640	1,028,376,448	1,672,206,000	1,537,680,800	928,639,200
Current portion of liabilities under finance lease agreements	25	57,205,890	59,337,586	84,092,301	10,230,295	10,717,752	11,109,263
Current portion of debentures	26	999,835,639	2,499,842,503	2,969,455,061	999,835,639	2,499,842,503	2,969,455,061
Short-term loans		97,700,000	88,700,000	-	-	-	-
Short-term loans from related parties	12	-	-	-	8,303,333,657	4,703,038,618	2,926,436,769
Income tax payable		726,682,651	631,985,257	473,257,464	138,543,809	82,257,572	34,281,001
Accrued expenses		4,855,181,484	2,796,219,548	2,483,562,669	1,151,084,489	592,525,182	533,890,576
Current portion of deferred income - membership		362,350,535	307,562,934	265,673,232	105,203,869	104,650,389	93,711,022
Other current liabilities	12	355,450,605	507,179,090	448,826,126	80,186,736	139,230,005	187,282,857
Total current liabilities		14,173,241,052	12,893,781,564	11,760,012,383	13,749,507,031	10,597,700,435	8,671,708,541
Non-current liabilities							
Long-term loans from financial institutions - net of current portion	24	7,737,989,124	9,371,612,676	7,623,657,555	7,697,531,600	9,306,925,600	7,326,342,400
Liabilities under finance lease agreements - net of current portion	25	46,944,936	101,402,802	75,332,355	6,528,177	15,404,412	18,368,151
Debentures - net of current portion	26	9,591,140,848	8,592,143,587	11,089,780,476	9,591,140,848	8,592,143,587	11,089,780,476
Convertible debentures - liability component	27	9,683,480,857	9,345,724,643	-	9,683,480,857	9,345,724,643	-
Provision for long-term employee benefits	28	1,529,572,833	1,356,592,542	1,204,104,085	348,778,971	245,985,250	238,374,454
Long-term portion of deferred income - membership		621,901,855	666,508,527	574,534,440	130,357,160	159,154,452	157,796,999
Deferred tax liabilities	33	2,485,688,533	1,843,793,861	1,393,591,718	201,577,534	231,950,440	146,832,381
Other non-current liabilities	12	290,007,199	199,998,971	143,131,253	197,496,263	54,733,977	76,170,563
Total non-current liabilities		31,986,726,185	31,477,777,609	22,104,131,882	27,856,891,410	27,952,022,361	19,053,665,424
Total liabilities		46,159,967,237	44,371,559,173	33,864,144,265	41,606,398,441	38,549,722,796	27,725,373,965

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of financial position (continued)

As at 31 December 2015

(Unit: Baht)

		Consolidated financial statements			Separate financial statements		
		As at	As at	As at	As at	As at	As at
	Note	31 December 2015	31 December 2014	1 January 2014	31 December 2015	31 December 2014	1 January 2014
Liabilities and shareholders' equity (continued)			(restated)			(restated)	
Shareholders' equity							
Share capital	29						
Registered							
16,497,868,714 ordinary shares of Baht 0.1 each							
(1 January 2014: 1,700,004,771 ordinary shares of Baht 1 each)		<u>1,649,786,871</u>	<u>1,649,786,871</u>	<u>1,700,004,771</u>	<u>1,649,786,871</u>	<u>1,649,786,871</u>	<u>1,700,004,771</u>
Issued and fully paid-up							
15,490,956,540 ordinary shares of Baht 0.1 each							
(1 January 2014: 1,549,095,654 ordinary shares of Baht 1 each)		1,549,095,654	1,549,095,654	1,549,095,654	1,549,095,654	1,549,095,654	1,549,095,654
Share premium							
Premium on ordinary shares		20,481,530,880	20,481,530,880	20,481,530,880	20,418,606,952	20,418,606,952	20,418,606,952
Difference from shareholding restructure		305,000,325	305,000,325	305,000,325	-	-	-
Retained earnings							
Appropriated - statutory reserve	31	170,000,477	170,000,477	170,000,477	170,000,477	170,000,477	170,000,477
Unappropriated		27,375,018,014	23,059,104,916	18,686,664,352	5,524,811,391	4,698,257,167	4,449,793,336
Other components of shareholders' equity		<u>3,795,303,504</u>	<u>1,215,423,175</u>	<u>(511,548,614)</u>	<u>1,619,776,872</u>	<u>1,533,613,530</u>	<u>719,764,480</u>
Equity attributable to owners of the Company		53,675,948,854	46,780,155,427	40,680,743,074	29,282,291,346	28,369,573,780	27,307,260,899
Non - controlling interests of the subsidiaries		<u>2,499,078,610</u>	<u>2,217,943,470</u>	<u>2,004,470,770</u>	-	-	-
Total shareholders' equity		<u>56,175,027,464</u>	<u>48,998,098,897</u>	<u>42,685,213,844</u>	<u>29,282,291,346</u>	<u>28,369,573,780</u>	<u>27,307,260,899</u>
Total liabilities and shareholders' equity		<u>#####</u>	<u>93,369,658,070</u>	<u>76,549,358,109</u>	<u>70,888,689,787</u>	<u>66,919,296,576</u>	<u>55,032,634,864</u>

The accompanying notes are an integral part of the financial statements.

.....

Directors

.....

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Income statement

For the year ended 31 December 2015

(Unit: Baht)

		Consolidated financial statements		Separate financial statements	
	Note	2015	2014	2015	2014
			(restated)		(restated)
Revenues					
Revenues from hospital operations	12	60,262,364,329	54,341,350,192	13,098,672,580	11,753,349,210
Other income	12				
Revenue from sales of goods and foods		2,594,595,226	1,712,248,291	46,874,033	47,590,019
Interest income and gain on sale of short-term investments		47,298,108	77,200,806	330,422,226	319,656,946
Dividend income	14, 15, 16	17,911,051	214,523,164	3,372,145,263	2,380,502,301
Gain on fair value adjustment of investments	15	208,747,913	-	-	-
Others		798,436,516	648,561,184	858,135,456	793,054,096
Total other income		3,666,988,814	2,652,533,445	4,607,576,978	3,540,803,362
Total revenues		63,929,353,143	56,993,883,637	17,706,249,558	15,294,152,572
Expenses					
Cost of hospital operations and goods sold	12	41,129,770,481	36,473,385,859	8,008,194,089	7,268,947,724
Administrative expenses	12	12,827,307,639	11,268,409,344	3,713,259,689	3,505,354,016
Total expenses		53,957,078,120	47,741,795,203	11,721,453,778	10,774,301,740
Profit before share of income from investments in associated companies, finance expenses and income tax expenses					
		9,972,275,023	9,252,088,434	5,984,795,780	4,519,850,832
Share of income from investments in associated companies	14	1,258,968,268	1,066,425,536	-	-
Profit before finance expenses and income tax expenses					
		11,231,243,291	10,318,513,970	5,984,795,780	4,519,850,832
Finance expenses	12	(1,135,865,592)	(976,282,861)	(1,219,901,237)	(1,034,304,851)
Profit before income tax expenses		10,095,377,699	9,342,231,109	4,764,894,543	3,485,545,981
Income tax expenses	33	(1,863,871,310)	(1,670,955,170)	(311,911,558)	(216,106,562)
Profit for the year		8,231,506,389	7,671,275,939	4,452,982,985	3,269,439,419
Profit attributable to:					
Equity holders of the Company		7,917,473,723	7,393,522,539	4,452,982,985	3,269,439,419
Non-controlling interests of the subsidiaries		314,032,666	277,753,400		
		8,231,506,389	7,671,275,939		
Basic earnings per share					
Profit attributable to equity holders of the Company	34	0.51	0.48	0.29	0.21
Weighted average number of ordinary shares (shares)		15,490,956,540	15,490,956,540	15,490,956,540	15,490,956,540

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of comprehensive income

For the year ended 31 December 2015

(Unit: Baht)

	Note	Consolidated financial statements		Separate financial statements	
		2015	2014	2015	2014
			(restated)		(restated)
Profit for the year		<u>8,231,506,389</u>	<u>7,671,275,939</u>	<u>4,452,982,985</u>	<u>3,269,439,419</u>
Other comprehensive income:					
<i>Other comprehensive income to be reclassified to profit or loss in subsequent periods</i>					
Gain on change in value					
of available-for-sale investments - net of income tax	16	78,176,021	289,809,996	86,163,342	305,494,421
Exchange differences on translation of financial statements in foreign currencies		91,035,792	17,898,287	-	-
Share of other comprehensive income from associated companies		<u>(53,713,502)</u>	<u>282,804,795</u>	<u>-</u>	<u>-</u>
Other comprehensive income to be reclassified to profit or loss in subsequent periods - net of income tax		<u>115,498,311</u>	<u>590,513,078</u>	<u>86,163,342</u>	<u>305,494,421</u>
<i>Other comprehensive income not to be reclassified to profit or loss in subsequent periods</i>					
Actuarial loss - net of income tax		(27,906,658)	-	(63,908,037)	-
Reversal revaluation surplus on land not used in operation		-	(77,172,820)	-	(77,172,820)
Transferred revaluation surplus on land to retained earnings due to disposal of land not used in operation		-	77,172,820	-	77,172,820
Gain on revaluation of land - net of income tax	18	<u>2,541,276,981</u>	<u>703,497,120</u>	<u>-</u>	<u>-</u>
Other comprehensive income not to be reclassified to profit or loss in subsequent periods - net of income tax		<u>2,513,370,323</u>	<u>703,497,120</u>	<u>(63,908,037)</u>	<u>-</u>
Other comprehensive income for the year		<u>2,628,868,634</u>	<u>1,294,010,198</u>	<u>22,255,305</u>	<u>305,494,421</u>
Total comprehensive income for the year		<u><u>10,860,375,023</u></u>	<u><u>8,965,286,137</u></u>	<u><u>4,475,238,290</u></u>	<u><u>3,574,933,840</u></u>
Total comprehensive income attributable to:					
Equity holders of the Company		10,467,897,876	8,660,732,943	<u>4,475,238,290</u>	<u>3,574,933,840</u>
Non-controlling interests of the subsidiaries		<u>392,477,147</u>	<u>304,553,194</u>		
		<u><u>10,860,375,023</u></u>	<u><u>8,965,286,137</u></u>		

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries
Statement of changes in shareholders' equity
For the year ended 31 December 2015

(Unit: Baht)

Consolidated financial statements																
Equity attributable to owners of the Company																
	Note	Other components of shareholders' equity														
		Other comprehensive income														
		Retained earnings		Surplus on changes in value of available-for-sale investments	Revaluation surplus on land	Exchange differences on translation of financial statements in foreign currency	Share of other components of equity from associated companies	Convertible debentures - equity component	Surplus investment over book value of subsidiary companies	Total other components of shareholders' equity	Total equity attributable to owners of the Company	Equity attributable to non-controlling interest of the subsidiaries	Total shareholders' equity			
		Issued and paid-up share capital	Premium on ordinary shares	Difference from shareholding restructure	Appropriated-statutory reserve	Unappropriated										
Balance as at 31 December 2013																
- As previously reported		1,549,095,654	20,481,530,880	305,000,325	170,000,477	18,686,664,352	(30,724,797)	2,039,861,309	(68,364,196)	113,932,085	-	(2,566,425,851)	(511,721,450)	40,680,570,238	1,963,034,544	42,643,604,782
Cummulative effect of change in accounting policy	4	-	-	-	-	-	-	-	172,836	-	-	-	172,836	172,836	41,436,226	41,609,062
Balance as at 31 December 2013		1,549,095,654	20,481,530,880	305,000,325	170,000,477	18,686,664,352	(30,724,797)	2,039,861,309	(68,191,360)	113,932,085	-	(2,566,425,851)	(511,548,614)	40,680,743,074	2,004,470,770	42,685,213,844
- As restated																
Profit for the year - restated		-	-	-	-	7,393,522,539	-	-	-	-	-	-	-	7,393,522,539	277,753,400	7,671,275,939
Other comprehensive income for the year - restated		-	-	-	-	77,066,433	289,806,430	599,617,462	17,808,897	282,911,182	-	-	1,190,143,971	1,267,210,404	26,799,794	1,294,010,198
Total comprehensive income for the year		-	-	-	-	7,470,588,972	289,806,430	599,617,462	17,808,897	282,911,182	-	-	1,190,143,971	8,660,732,943	304,553,194	8,965,286,137
Convertible debentures - equity component	27	-	-	-	-	-	-	-	-	-	585,527,449	-	585,527,449	585,527,449	-	585,527,449
Dividend paid	30	-	-	-	-	(3,098,148,408)	-	-	-	-	-	-	-	(3,098,148,408)	-	(3,098,148,408)
Share of Interest paid for convertible debentures treated as equity securities from an associated company		-	-	-	-	-	-	-	-	(7,783,870)	-	-	(7,783,870)	(7,783,870)	-	(7,783,870)
Change in non-controlling interests of subsidiaries from purchase investments in subsidiaries		-	-	-	-	-	-	-	-	(6,008,920)	-	(34,906,841)	(40,915,761)	(40,915,761)	26,567,200	(14,348,561)
Decrease in non-controlling interests of subsidiaries from dividend of subsidiaries		-	-	-	-	-	-	-	-	-	-	-	-	-	(117,647,694)	(117,647,694)
Balance as at 31 December 2014 - As restated		1,549,095,654	20,481,530,880	305,000,325	170,000,477	23,059,104,916	259,081,633	2,639,478,771	(50,382,463)	383,050,477	585,527,449	(2,601,332,692)	1,215,423,175	46,780,155,427	2,217,943,470	48,998,098,897

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity (continued)

For the year ended 31 December 2015

(Unit: Baht)

Consolidated financial statements															
Equity attributable to owners of the Company															
Other components of shareholders' equity															
Other comprehensive income															
Surplus on changes in value of available-for-sale investments															
Exchange differences on translation of financial statements in foreign currency															
Share of other components of equity from associated companies															
Convertible debentures - equity component															
Surplus of investment over book value of subsidiary companies															
Total other components of shareholders' equity															
Total equity attributable to owners of the Company															
Equity attributable to non-controlling interest of the subsidiaries															
Total shareholders' equity															
Note	Issued and paid-up share capital	Premium on ordinary shares	Difference from shareholding restructure	Appropriated-statutory reserve	Unappropriated Retained earnings	investments	Revaluation surplus on land	foreign currency	companies	component	companies	equity	the Company	subsidiaries	equity
Balance as at 31 December 2014															
- As previously reported	1,549,095,654	20,481,530,880	305,000,325	170,000,477	23,059,104,916	259,081,633	2,639,478,771	(50,711,691)	383,050,477	585,527,449	(2,601,332,692)	1,215,093,947	46,779,826,199	2,174,432,672	48,954,258,871
Cummulative effect of change in accounting policy	4	-	-	-	-	-	-	329,228	-	-	-	329,228	329,228	43,510,798	43,840,026
Balance as at 31 December 2014															
- As restated	1,549,095,654	20,481,530,880	305,000,325	170,000,477	23,059,104,916	259,081,633	2,639,478,771	(50,382,463)	383,050,477	585,527,449	(2,601,332,692)	1,215,423,175	46,780,155,427	2,217,943,470	48,998,098,897
Profit for the year	-	-	-	-	7,917,473,723	-	-	-	-	-	-	-	7,917,473,723	314,032,666	8,231,506,389
Other comprehensive income for the year	-	-	-	-	(39,039,901)	78,174,126	2,470,623,555	87,811,675	(47,145,302)	-	-	2,589,464,054	2,550,424,153	78,444,481	2,628,868,634
Total comprehensive income for the year	-	-	-	-	7,878,433,822	78,174,126	2,470,623,555	87,811,675	(47,145,302)	-	-	2,589,464,054	10,467,897,876	392,477,147	10,860,375,023
Dividend paid	30	-	-	-	(3,562,520,724)	-	-	-	-	-	-	-	(3,562,520,724)	-	(3,562,520,724)
Share of Interest paid for convertible debentures treated as equity securities from an associated company	-	-	-	-	-	-	-	-	(7,783,870)	-	-	(7,783,870)	(7,783,870)	-	(7,783,870)
Change in non-controlling interests of subsidiaries from purchase investments in subsidiaries	-	-	-	-	-	-	-	-	-	-	(1,799,855)	(1,799,855)	(1,799,855)	30,767,687	28,967,832
Decrease in non-controlling interests of subsidiaries from dividend of subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	(142,109,694)	(142,109,694)
Balance as at 31 December 2015	1,549,095,654	20,481,530,880	305,000,325	170,000,477	27,375,018,014	337,255,759	5,110,102,326	37,429,212	328,121,305	585,527,449	(2,603,132,547)	3,795,303,504	53,675,948,854	2,499,078,610	56,175,027,464

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity (continued)

For the year ended 31 December 2015

(Unit: Baht)

Separate financial statements									
	Other components of shareholders' equity								
	Other comprehensive income								
	Surplus								
	on changes								
Note	Retained earnings				in value of		Convertible	Total other	Total
	Issued and paid-up share capital	Premium on ordinary shares	Appropriated- statutory reserve	Unappropriated	available-for- sale	Revaluation surplus on land	debentures - equity component	components of shareholders' equity	shareholders' equity
Balance as at 31 December 2013	1,549,095,654	20,418,606,952	170,000,477	4,449,793,336	(31,269,722)	751,034,202	-	719,764,480	27,307,260,899
Profit for the year	-	-	-	3,269,439,419	-	-	-	-	3,269,439,419
Other comprehensive income for the year	-	-	-	77,172,820	305,494,421	(77,172,820)	-	228,321,601	305,494,421
Total comprehensive income for the year	-	-	-	3,346,612,239	305,494,421	(77,172,820)	-	228,321,601	3,574,933,840
Convertible debentures - equity component	27	-	-	-	-	-	585,527,449	585,527,449	585,527,449
Dividend paid	30	-	-	(3,098,148,408)	-	-	-	-	(3,098,148,408)
Balance as at 31 December 2014	1,549,095,654	20,418,606,952	170,000,477	4,698,257,167	274,224,699	673,861,382	585,527,449	1,533,613,530	28,369,573,780
Balance as at 31 December 2014	1,549,095,654	20,418,606,952	170,000,477	4,698,257,167	274,224,699	673,861,382	585,527,449	1,533,613,530	28,369,573,780
Profit for the year	-	-	-	4,452,982,985	-	-	-	-	4,452,982,985
Other comprehensive income for the year	-	-	-	(63,908,037)	86,163,342	-	-	86,163,342	22,255,305
Total comprehensive income for the year	-	-	-	4,389,074,948	86,163,342	-	-	86,163,342	4,475,238,290
Dividend paid	30	-	-	(3,562,520,724)	-	-	-	-	(3,562,520,724)
Balance as at 31 December 2015	1,549,095,654	20,418,606,952	170,000,477	5,524,811,391	360,388,041	673,861,382	585,527,449	1,619,776,872	29,282,291,346

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of cash flows

For the year ended 31 December 2015

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
		(restated)		(restated)
Cash flows from operating activities				
Profit before income tax expenses	10,095,377,699	9,342,231,109	4,764,894,543	3,485,545,981
Adjustments to reconcile profit before income tax expenses to net cash provided by (paid from) operating activities:				
Depreciation and amortisation expenses	4,386,699,641	3,716,362,849	820,488,759	709,023,331
Write-off of assets	25,475,985	47,464,288	1,985,758	4,363,172
Bad debts and doubtful debts	117,004,688	128,233,231	21,727,872	54,217,765
Loss on impairment of investments	17,493,668	-	-	58,967,211
Loss on impairment of assets	2,700,000	94,960,933	2,700,000	14,018,081
Reserve (reversal) of loss on deteriorated inventories	1,804,776	55,966	384,886	(455,083)
Amortisation of deferred income - membership	(459,030,249)	(422,498,126)	(141,464,631)	(128,523,162)
Share of income from investments in associated companies	(1,258,968,268)	(1,066,425,536)	-	-
Gain on disposal of investments in subsidiary and associated companies	(57,328,697)	-	-	-
Gain on fair value adjustment of investments	(208,747,913)	-	-	-
Amortisation of expense for debentures and convertible debentures	30,731,171	11,051,627	30,731,171	11,051,627
Gain on disposal of property, premises and equipment and land not used in operation	(12,936,066)	(108,751,484)	(3,077,597)	(95,241,103)
Gain on fair value adjustment of investment properties	(9,000,000)	(2,500,000)	(9,000,000)	(2,500,000)
Unrealised loss (gain) on foreign exchange	(12,289,509)	17,753,400	(13,282,367)	28,232,239
Long-term employee benefit expenses	175,075,751	162,786,112	30,473,623	29,869,194
Annual leave expenses	14,111,750	14,290,881	2,633,255	6,037,033
Interest income	(47,298,108)	(77,200,806)	(330,422,226)	(319,656,946)
Dividend income	(17,911,051)	(214,523,164)	(3,372,145,263)	(2,380,502,301)
Interest expense	<u>1,135,865,592</u>	<u>976,282,861</u>	<u>1,219,901,237</u>	<u>1,034,304,851</u>
Profit from operating activities before changes in operating assets and liabilities	13,918,830,860	12,619,574,141	3,026,529,020	2,508,751,890

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of cash flows (continued)

For the year ended 31 December 2015

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
		(restated)		(restated)
Cash flows from operating activities (continued)				
Decrease (increase) in operating assets				
Trade and other receivables	(851,648,651)	(863,084,132)	(444,564,863)	(232,969,272)
Inventories	(177,458,434)	(79,977,627)	(1,113,408)	2,749,469
Other current assets	12,069,598	(69,399,311)	(8,005,357)	(1,359,108)
Other non-current assets	8,856,891	32,546,760	25,339,704	(23,641,168)
Increase (decrease) in operating liabilities				
Trade and other payables	164,250,632	415,680,189	39,369,528	26,599,706
Accrued expenses	2,080,806,887	254,877,949	558,209,220	69,633,075
Deferred income - membership	469,211,177	556,361,915	113,220,818	140,819,984
Other current liabilities	(155,600,687)	(12,581,674)	(59,043,269)	(48,052,853)
Provision for long-term employee benefits	(34,365,408)	(60,035,476)	(7,564,948)	(22,258,398)
Other non-current liabilities	90,008,231	(26,356,767)	142,762,288	(21,436,583)
Net cash from operating activities	15,524,961,096	12,767,605,967	3,385,138,733	2,398,836,742
Cash received from interest income	48,659,354	84,277,189	334,973,696	331,435,069
Cash paid for interest expenses	(831,711,376)	(908,310,983)	(917,306,213)	(977,855,954)
Cash received from tax refund	8,454,141	11,786,111	-	-
Cash paid for income tax expenses	(1,884,710,186)	(1,551,935,419)	(299,619,963)	(161,506,078)
Net cash from operating activities	12,865,653,029	10,403,422,865	2,503,186,253	1,590,909,779

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of cash flows (continued)

For the year ended 31 December 2015

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
		(restated)		(restated)
Cash flows from investing activities				
Decrease (increase) in short-term investments	1,849,337,406	(1,757,242,102)	1,581,938,905	(1,583,278,960)
Increase in restricted financial institution deposits	(32,181,995)	(8,841,763)	-	-
Decrease in long-term financial institution deposits	-	10,418,441	-	-
Dividend received	816,884,560	609,954,463	3,372,145,263	2,380,502,301
Cash received from disposal of investments in subsidiary and associated compai	112,847,900	-	-	-
Cash received from disposal of other long-term investment	25,000,000	-	-	-
Cash paid for purchase of investments in subsidiaries, associates and other company	(1,684,535,404)	(7,449,927,544)	(2,513,306,522)	(8,604,684,513)
Cash paid for investment property	(2,128,399)	(187,250)	(2,128,399)	(187,250)
Cash received from disposal of property, premises and equipment	71,927,319	44,794,515	12,009,217	9,426,827
Cash received from disposal of land and buildings not used in operation	-	399,157,000	-	399,157,000
Cash paid for purchase of property, premises and equipment	(5,976,203,862)	(7,798,492,548)	(1,110,600,462)	(1,165,041,195)
Cash paid for leasehold rights	(3,000,000)	(19,453,037)	-	-
Decrease (increase) in short-term loans to related parties	-	-	428,770,408	(842,991,036)
Increase in long-term loans to related parties	-	-	(1,180,710,000)	(997,090,150)
Cash received from long-term loans to related parties	-	-	811,608,800	889,898,368
Cash paid for purchase of intangible assets	(360,811,236)	(186,540,669)	(135,541,661)	(72,158,558)
Net cash from (used in) investing activities	(5,182,863,711)	(16,156,360,494)	1,264,185,549	(9,586,447,166)

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries

Statement of cash flows (continued)

For the year ended 31 December 2015

(Unit: Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014 (restated)	2015	2014 (restated)
Cash flows from financing activities				
Cash received from short-term loans	9,000,000	17,500,000	-	-
Increase (decrease) in short-term loans from related parties	-	(53,762,425)	3,600,295,038	1,776,601,849
Cash received from bank overdraft and short-term loans from financial institutions	8,955,244,748	5,303,020,895	8,900,000,000	5,300,000,000
Repayment of bank overdraft and short-term loans from financial institutions	(8,903,020,895)	(5,546,702,887)	(8,900,000,000)	(5,300,000,000)
Cash received from long-term loans from financial institutions	1,000,000	3,644,510,600	-	3,644,510,600
Repayment of long-term loans from financial institutions	(1,585,964,446)	(1,551,686,031)	(1,537,680,800)	(1,072,639,200)
Repayments of liabilities under finance lease agreements	(77,385,378)	(102,291,765)	(10,251,142)	(13,492,531)
Cash received from issue of debentures	1,997,415,349	-	1,997,415,349	-
Cash paid for redemption of debentures	(2,500,000,000)	(2,970,000,000)	(2,500,000,000)	(2,970,000,000)
Cash received from issue of convertible debentures	-	9,835,089,103	-	9,835,089,103
Cash paid for investment in subsidiary companies from non - controlling interests	45,727,119	(75,640,602)	-	-
Dividend paid	(3,562,520,724)	(3,098,148,408)	(3,562,520,724)	(3,098,148,408)
Dividend paid by subsidiaries to non-controlling interests	(142,109,694)	(117,647,694)	-	-
Net cash from (used in) financing activities	(5,762,613,921)	5,284,240,786	(2,012,742,279)	8,101,921,413
Net increase (decrease) in cash and cash equivalents	1,920,175,397	(468,696,843)	1,754,629,523	106,384,026
Cash and cash equivalents at beginning of year	3,608,367,714	4,077,064,557	1,862,514,806	1,756,130,780
Cash and cash equivalents at end of year	5,528,543,111	3,608,367,714	3,617,144,329	1,862,514,806

Supplemental cash flows information:

Non-cash items:

Assets acquired under finance lease agreements	20,320,394	69,498,570	111,495	8,980,891
Increase (decrease) in accounts payable - property, premises and equipment	487,586,062	(196,929,144)	326,379,198	(31,132,167)
Increase (decrease) in payable to construction - retention	(47,098,504)	14,299,604	2,157,221	(22,043,314)
Dividend receivable	-	9,100,000	-	-
Conversion of long-term loan to subsidiary to investment in a subsidiary company	-	-	-	474,897,000

The accompanying notes are an integral part of the financial statements.

Bangkok Dusit Medical Services Public Company Limited and its subsidiaries
Notes to consolidated financial statements
For the year ended 31 December 2015

1. General information

Bangkok Dusit Medical Services Public Company Limited ("the Company") is a public company under Thai laws and domiciled in Thailand. The Company is principally engaged in the hospital business. The registered office of the Company is at 2, Soi Soonvijai 7, New Petchburi Road, Bang Kapi, Huaykwang, Bangkok.

2. Basis of preparation

- 2.1 The financial statements have been prepared in accordance with Thai Financial Reporting Standards enunciated under the Accounting Profession Act B.E. 2547 and their presentation has been made in compliance with the stipulations of the Notification of the Department of Business Development dated 28 September 2011, issued under the Accounting Act B.E. 2543.

The financial statements in Thai language are the official statutory financial statements of the Company. The financial statements in English language have been translated from the Thai language financial statements.

The financial statements have been prepared on a historical cost basis except where otherwise disclosed in the accounting policies.

2.2 Basis of consolidation

- a) The consolidated financial statements include the financial statements of Bangkok Dusit Medical Services Public Company Limited ("the Company") and the following subsidiaries ("the subsidiaries") as follows:

Company's name	Nature of business	Percentage of shareholding (percent)	
		<u>2015</u>	<u>2014</u>
<u>Held by the Company</u>			
Samitivej Public Co., Ltd.	Hospital	95.76	95.76
Bangkok Hospital Hatyai Co., Ltd.	Hospital	98.81	98.80
Bangkok Phuket Hospital Co., Ltd.	Hospital	99.69	99.69
BNH Medical Center Co., Ltd.	Hospital	91.48	91.48
Bangkok Phrapradaeng Hospital Co., Ltd.	Hospital	84.00	84.00
Bangkok Pattaya Hospital Co., Ltd.	Hospital	97.27	97.27
Bangkok Rayong Hospital Co., Ltd.	Hospital	100.00	100.00
Bangkok Samui Hospital Co., Ltd.	Hospital	100.00	100.00
Bangkok Trat Hospital Co., Ltd.	Hospital	99.76	99.76
Wattanavej Co., Ltd.	Hospital	99.69	99.69
Bangkok Ratchasima Hospital Co., Ltd.	Hospital	91.36	91.36

Company's name	Nature of business	Percentage of shareholding (percent)	
		<u>2015</u>	<u>2014</u>
<u>Held by the Company (continued)</u>			
National Healthcare Systems Co., Ltd. (held by the Company at 74.02% and indirectly held by subsidiaries at 24.66%)	Central lab	74.02	74.02
Bio Molecular Laboratories (Thailand) Co., Ltd.	Central lab	95.00	95.00
Angkor Pisith Co., Ltd.	Hospital	80.00	80.00
Phnom Penh Medical Services Co., Ltd.	Hospital	100.00	100.00
Royal Rattanak Medical Services Co., Ltd.	Hospital	70.00	70.00
B.D.M.S. International Medical Services Co., Ltd.	Not yet operate	100.00	100.00
BDMS Accounting Co., Ltd.	Accounting service	100.00	100.00
Bangkok Health Insurance Public Co., Ltd.	Health insurance	99.97	99.97
Royal Bangkok Healthcare Co., Ltd.	Investment	100.00	100.00
Greenline Synergy Co., Ltd.	Technology and information service	100.00	100.00
Bangkok Hospital Kao Yai Co., Ltd.	Not yet operate	100.00	100.00
BDMS Training Co., Ltd.	Training business	100.00	100.00
Prasit Patana Public Co., Ltd.	Investment	98.56	98.52
Paolo Medic Co., Ltd.	Hospital	100.00	100.00
Paolo Samutprakarn Co., Ltd.	Hospital	93.64	93.61
Siam Medical Co., Ltd.	Hospital	85.71	85.71
Thai Medical Center Public Co., Ltd.	Hospital	99.76	99.76
Bangkok Premier Life Insurance Broker Co., Ltd.	Life insurance broker	100.00	100.00
Bangkok Hospital Chiangmai Co., Ltd.	Hospital	100.00	100.00
Bangkok Hospital Udon Co., Ltd.	Hospital	100.00	100.00
Bangkok Khon Kaen Hospital Co., Ltd.	Hospital	100.00	100.00

Company's name	Nature of business	Percentage of shareholding (percent)	
		<u>2015</u>	<u>2014</u>
<u>Held by the Company (continued)</u>			
The Medicpharma Co., Ltd.	Production and distribution of medicines	87.05	86.89
Thonburi Medical Center Public Co., Ltd. (held by the Company at 29.01% and indirectly held by subsidiary at 29.02%)	Hospital	29.01	29.01
Bangkok Hospital Surat Co., Ltd.	Not yet operate	100.00	100.00
BDMS Inter Pte. Ltd.	Investment	100.00	100.00
N Health Asia Pte. Ltd.	Investment	100.00	100.00
Samitivej Chonburi Co., Ltd.	Hospital	100.00	100.00
Bangkok Hospital Phitsanulok Co., Ltd.	Hospital	100.00	100.00
Bangkok Hospital Sanamchan Co., Ltd.	Hospital	100.00	100.00
Bangkok Phuket International Hospital Co., Ltd.	Hospital	100.00	100.00
Bangkok Save Drug Co., Ltd.	Investment	100.00	100.00
S.R. Property Investment Co., Ltd.	Real estate	49.00	49.00
Siem Reap Land Investment Co., Ltd.	Real estate	49.00	49.00
Phnom Penh First Property Co., Ltd.	Real estate	49.00	49.00
Bangkok Helicopter Services Co., Ltd.	Air transportation services	49.00	49.00
Bangkok Hospital Chiangrai Co., Ltd.	Not yet operate	100.00	-
Bangkok Hospital Muangraj Co., Ltd.	Hospital	100.00	-
<u>Held by subsidiaries</u>			
National Healthcare Systems Co., Ltd.	Central lab	25.97	25.97
Samitivej Sriracha Co., Ltd.	Hospital	69.75	69.75
Irving Sheridan SE Co., Ltd.	Assets management for healthcare business	96.03	96.03
First Health Food Co., Ltd.	Restaurant and distributing health food products and facility management and investments	100.00	100.00
Sodexo Healthcare Support Services (Thailand) Co., Ltd.	Restaurant and distributing health food products and facility management	-	74.00
SV Holding Co., Ltd.	Investment	100.00	100.00

Company's name	Nature of business	Percentage of shareholding (percent)	
		<u>2015</u>	<u>2014</u>
<u>Held by subsidiaries (continued)</u>			
A.N.B. Laboratories Co., Ltd.	Manufacturer and distributor of medicine and pharmaceutical products	100.00	100.00
Thonburi Medical Center Public Co., Ltd.	Hospital	29.02	29.02
Phyathai 1 Hospital Co., Ltd.	Hospital	100.00	100.00
Phyathai 2 Hospital Co., Ltd.	Hospital	99.18	99.16
Phyathai 3 Hospital Co., Ltd.	Hospital	98.23	98.23
Sriracha Nakorn General Hospital Public Co., Ltd.	Hospital	74.49	74.34
N Health Cambodia Co., Ltd.	Central Lab	100.00	100.00
Tepakorn Hospital Co., Ltd.	Hospital	44.53	44.53
Save Drug Center Co., Ltd.	Retailer of medicine and pharmaceutical products	100.00	100.00
N Health Pathology Co., Ltd.	Central Lab	95.00	95.00
Samitivej International Co., Ltd.	Clinic	80.00	80.00
N Health Myanmar Co., Ltd.	Central Lab	60.00	60.00

All subsidiaries incorporated in Thailand except B.D.M.S. International Medical Services Co., Ltd., Angkor Pisith Co., Ltd., Phnom Penh Medical Services Co., Ltd., Royal Rattanak Medical Services Co., Ltd. and N Health Cambodia Co., Ltd. which were registered in Cambodia and BDMS Inter Pte. Ltd. and N Health Asia Pte. Ltd. registered in Singapore and Samitivej International Co., Ltd. and N Health Myanmar Co., Ltd. registered in Republic of the Union of Myanmar.

- b) The Company is deemed to have control over an investee or subsidiaries if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns.
- c) Subsidiaries are fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases.
- d) The financial statements of the subsidiaries are prepared using the same significant accounting policies as the Company.

- e) The assets and liabilities in the financial statements of overseas subsidiary companies are translated to Baht using the exchange rate prevailing on the end of reporting period, and revenues and expenses translated using monthly average exchange rates. The resulting differences are shown under the caption of “Exchange differences on translation of financial statements in foreign currency” in the statements of changes in shareholders’ equity.
 - f) Material balances and transactions between the Company and its subsidiaries have been eliminated from the consolidated financial statements.
 - g) Non-controlling interests represent the portion of profit or loss and net assets of the subsidiaries that are not held by the Company and are presented separately in the consolidated profit or loss and within shareholders’ equity in the consolidated statement of financial position.
 - h) In recording the acquisition of additional shares of subsidiaries (repurchase of shares from minority shareholders) when the fair value of the net assets acquired is lower than the cost of the investment the difference has been presented in other components of shareholders' equity in the statement of financial position under the caption of “Surplus on investments in subsidiary companies arising as a result of acquisition of additional shares at a price higher than net book value at the acquisition date”. When the fair value of the net assets acquired is higher than the cost of the investment the difference has been presented in other components of shareholders' equity in the statement of financial position under the caption of “Lower of investment in subsidiary companies arising as a result of acquisition of additional shares at a price lower than net book value at the acquisition date”.
- 2.3 The separate financial statements present investments in subsidiaries and associates under the cost method.

3. New financial reporting standards

Below is a summary of financial reporting standards that became effective in the current accounting year and those that will become effective in the future.

(a) Financial reporting standards that became effective in the current year

The Company and its subsidiaries have adopted the revised (revised 2014) and new financial reporting standards issued by the Federation of Accounting Professions which become effective for fiscal years beginning on or after 1 January 2015. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards, with most of the changes directed towards revision of wording and terminology, and provision of interpretations and accounting guidance to users of standards. The adoption of these financial reporting standards does not have any significant impact on the Company's and its subsidiaries' financial statements. However, some of these standards involve changes to key principles, which are summarised below:

TAS 19 (revised 2014) Employee Benefits

This revised standard requires that the entity recognise actuarial gains and losses immediately in other comprehensive income while the former standard allowed the entity to recognise such gains and losses immediately in either profit or loss or other comprehensive income, or to recognise them gradually in profit or loss.

This revised standard does not have any impact on the financial statements as the Company and its subsidiaries already recognise actuarial gains and losses immediately in other comprehensive income.

TFRS 10 Consolidated Financial Statements

TFRS 10 prescribes requirements for the preparation of consolidated financial statements and replaces the content of TAS 27 *Consolidated and Separate Financial Statements* dealing with consolidated financial statements. This standard changes the principles used in considering whether control exists. Under this standard, an investor is deemed to have control over an investee if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns, even if it holds less than half of the shares or voting rights. This important change requires the management to exercise a lot of judgement when reviewing whether the Company and its subsidiaries have control over investees and determining which entities have to be included in preparation of the consolidated financial statements.

The management of the Company reviewed whether the Company has control over investees in accordance with the principles of this standard and determined that the Company has control over 4 companies, formerly considered associates, which are Bangkok Helicopter Services Co., Ltd., S.R. Property Investment Co., Ltd., Siem Reap Land Investment Co., Ltd. and Phnom Penh First Property Co., Ltd. This is because the Company is a major shareholder and has the ability to direct the significant activities of such companies. As a result, such companies are deemed to be subsidiaries of the Group and have to be included in the consolidated financial statements from the date on which the Company assumed control (the date on which the Company invested in these entities). The Company restated the prior period's financial statements, presented as comparative information, to reflect the effect of this change. The cumulative effect of changes in accounting policies is presented in Note 4 to the financial statements.

TFRS 12 Disclosure of Interests in Other Entities

This standard stipulates disclosures relating to an entity's interests in subsidiaries, joint arrangements and associates, including structured entities.

This standard does not have any significant impact on the Company's and its subsidiaries' financial statements.

TFRS 13 Fair Value Measurement

This standard provides guidance on how to measure fair value and stipulates disclosures related to fair value measurement. Entities are to apply the guidance under this standard if they are required by other financial reporting standards to measure their assets or liabilities at fair value. The effects of the adoption of this standard are to be recognised prospectively.

This standard does not have any significant impact on the Company's and its subsidiaries' financial statements.

(b) Financial reporting standard that will become effective in the future

During the current year, the Federation of Accounting Professions issued a number of the revised (revised 2015) and new financial reporting standards and accounting treatment guidance which is effective for fiscal years beginning on or after 1 January 2016. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards. The Company's and its subsidiaries' management believes that the revised and new financial reporting standards and accounting treatment guidance will not have any significant impact on the financial statements when it is initially applied.

4. Cumulative effects of changes in accounting policies due to the adoption of new financial reporting standards

As described in Note 3 to the financial statements, during the current year, the Company and its subsidiaries have changed some of their accounting policies, as a result of the adoption of new financial reporting standards. The cumulative effect of the change has been separately presented in the statements of changes in shareholders' equity.

The amounts of adjustments affecting the statements of financial position and the statements of comprehensive income are summarised below.

	(Unit: Million Baht)	
	Consolidated financial statements	
	As at 31 December 2014	As at 1 January 2014
Statements of financial position:		
Increase in current assets	19	18
Increase in non-current assets	123	132
Total increase in assets	142	150
Increase (decrease) in current liabilities	15	(1)
Increase in non-current liabilities	83	110
Increase in other components of shareholders' equity	-	-
Increase in non-controlling interests of the subsidiaries	44	41
Total increase in liabilities and shareholders' equity	142	150

	(Unit: Million Baht)	
	Separate financial statements	
	As at 31 December 2014	As at 1 January 2014
Statements of financial position:		
Increase in current assets	-	-
Increase in non-current assets	-	-
Total increase in assets	-	-
Increase in current liabilities	-	-
Increase in non-current liabilities	-	-
Increase in other components of shareholders' equity	-	-
Total increase in liabilities and shareholders' equity	-	-

	(Unit: Million Baht)	
	Consolidated financial statements	Separate financial statements
	For the year ended 31 December 2014	For the year ended 31 December 2014
Statements of comprehensive income		
Profit or loss:		
Increase in other income	19	-
Increase in cost and expenses	(16)	-
Decrease in share of income from investments in associated companies	(1)	-
Increase in profit	2	-
Comprehensive income attributable to:		
Equity holders of the Company	-	-
Increase in profit attributable to non-controlling interests of the subsidiaries	2	-
Earnings per share (Baht):		
Increase (decrease) in basic earnings per share	-	-

5. Significant accounting policies

5.1 Revenue recognition

Hospital operations

Revenues from hospital operations, mainly consisting of medical fees, hospital room sales and medicine sales, are recognised as income when services have been rendered or medicine delivered.

Revenue from sales of goods and foods

Sales of goods and foods are recognised when the significant risks and rewards of ownership of the goods have passed to the buyer. Sales are the invoiced value, excluding value added tax, of goods and food supplied after deducting discounts.

Service income

Service income is recognised when services have been rendered.

Membership income

Membership income is cash receipt from sales of membership cards which initially recorded as deferred income and gradually amortised to income within membership period. For cash received in advance from the Life Privilege membership program is amortised to income over a period of 10 years.

Rental and related service income

Rental and service income are recognised proportionately over the term of the lease and service agreements.

Interest income

Interest income is recognised on an accrual basis based on the effective rate.

Dividends

Dividends are recognised when the right to receive the dividends is established.

5.2 Cash and cash equivalents

Cash and cash equivalents consist of cash in hand and cash at financial institutions and highly liquid investment with an original maturity of 3 months or less and not subject to withdrawal restrictions.

5.3 Trade accounts receivable and allowance for doubtful accounts

Trade accounts receivable are stated at the net realisable value. Allowance for doubtful accounts is provided for the estimated losses that may be incurred in collection of receivables. The allowance is generally based on collection experiences and analysis of debt aging.

5.4 Inventories

Inventories are valued at lower of cost (weighted average basis) or net realisable value. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale.

5.5 Investments

- a) Investments in securities held for trading are stated at fair value. Changes in the fair value of these securities are recorded in profit or loss.
- b) Investments in available-for-sale securities are stated at fair value. Changes in the fair value of these securities are recorded in other comprehensive income, and will be recorded in profit or loss when the securities are sold.

- c) Investments in debt securities, both due within one year and expected to be held to maturity, are recorded at amortised cost. The premium/discount on debt securities is amortised/accreted by the effective rate method with the amortised/accreted amount presented as an adjustment to the interest income.
- d) Investments in non-marketable equity securities, which the Company classifies as other investments, are stated at cost net of allowance for loss on diminution in value (if any).
- e) Investments in associates are accounted for in the consolidated financial statements using the equity method.
- f) Investments in subsidiaries and associates are accounted for in the separate financial statements using the cost method.

The weighted average method is used for computation of the cost of investments.

The fair value of marketable securities is based on the latest bid price of the last working day of the year. The fair value of unit trusts is determined from their net asset value of the last working day of the year.

5.6 Investment properties

Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are stated at fair value. Any gains or losses arising from changes in the value of investment properties are recognised in profit or loss when incurred.

On disposal of investment properties, the difference between the net disposal proceeds and the carrying amount of the asset is recognised in profit or loss in the period when the asset is derecognised.

5.7 Property, premises and equipment/Depreciation

Land is stated at revalued amount. Buildings and equipment are stated at cost less accumulated depreciation and allowance for loss on impairment of assets (if any).

Land initially recorded at cost on the acquisition date, and subsequently revalued by an independent professional appraiser to its fair values. Revaluations are made with sufficient regularity to ensure that the carrying amount does not differ materially from fair value at the end of reporting period.

Differences arising from the revaluation are dealt with in the financial statements as follows:

- When an asset's carrying amount is increased as a result of a revaluation of the Company and its subsidiaries' assets, the increase is credited directly to other comprehensive income under the heading of "Revaluation surplus on land". However, a revaluation increase will be recognised as income to the extent that it reverses a revaluation decrease of the same asset previously recognised as an expense.

- When an asset's carrying amount is decreased as a result of a revaluation of the Company and its subsidiaries' assets, the decrease is recognised in profit or loss. However, the revaluation decrease is charged to the other comprehensive income to the extent that it does not exceed an amount already held in "Revaluation surplus on land" in respect of the same asset.

Depreciation of premises and equipment is calculated by reference to their cost on a straight-line basis over the following estimated useful lives:

Land improvements	5 - 30 years
Building, structures and building improvements	5 - 50 years
Medical tools and equipment and machines	3 - 10 years
Helicopter	20 years
Helicopter spare parts and equipment	5 years
Structure equipment, furniture and office equipment	3 - 15 years
Vehicles	5 - 8 years

Depreciation attributed to the original cost portion is included in determining income.

No depreciation is provided on land and fixed assets under construction and installation.

An item of property, premises and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on disposal of an asset is included in profit or loss when the asset is derecognised.

5.8 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the respective assets. All other borrowing costs are expensed in the period they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

5.9 Intangible assets

Intangible assets acquired through business combination are initially recognised at their fair value on the date of business acquisition while intangible assets acquired in other cases are recognised at cost. Following the initial recognition, the intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (if any).

Intangible assets with finite lives are amortised on a systematic basis over the economic useful life and tested for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method of such intangible assets are reviewed at least at each financial year end. The amortisation expense is charged to profit or loss.

The intangible asset with finite useful lives is as follow:

Computer software	5 - 10 years
-------------------	--------------

Intangible assets with indefinite useful lives are not amortised such as commercial rights, but are tested for impairment annually either individually or at the cash generating unit level. The assessment of indefinite useful lives of the intangible assets is reviewed annually.

5.10 Goodwill / Business combination

Business combinations are accounted for using the acquisition method with the cost of the acquisition being the fair value at the acquisition date of consideration transferred, and the amount of any non-controlling interest in the acquiree. For each business combination, the acquirer measures the non-controlling interest, if any, in the acquiree either at fair value or at the proportionate share of the acquiree's identifiable net assets.

Acquisition-related costs are accounted for as expenses in the periods in which the costs are incurred and the services are received.

Goodwill is initially recorded at cost, which equals to the excess of cost of business combination over the fair value of the net assets acquired. If the fair value of the net assets acquired exceeds the cost of business combination, the excess is immediately recognised as gain in profit or loss.

Goodwill is carried at cost less any accumulated impairment losses. Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired.

For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the Company's cash generating units (or group of cash-generating units) that are expected to benefit from the synergies of the combination. The Company estimates the recoverable amount of each cash-generating unit (or group of cash-generating units) to which the goodwill relates. Where the recoverable amount of the cash-generating unit is less than the carrying amount, an impairment loss is recognised in profit or loss. Impairment losses relating to goodwill cannot be reversed in future periods.

5.11 Related party transactions

Related parties comprise enterprises and individuals that control or are controlled by the Company, whether directly or indirectly, or which are under common control with the Company.

They also include associated companies and individuals which directly or indirectly own a voting interest in the Company that gives them significant influence over the Company, key management personnel, directors and officers with authority in the planning and direction of the Company's operations.

5.12 Long-term rental agreements

Leases of property, premises or equipment which transfer substantially all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalised at the lower of the fair value of the leased assets and the present value of the minimum lease payments. The outstanding rental obligations, net of finance charges, are included in other long-term payables, while the interest element is charged to profit or loss over the lease period. The property, premises or equipment acquired under finance leases is depreciated over the useful life of the assets.

5.13 Operating leases

Leases of assets where a significant portion of the risks and rewards of ownership is retained by the lessor are classified as operating leases. Payments made under operating leases are recognised as expenses in profit or loss on a straight line basis over the period of the lease.

5.14 Impairment of assets

At the end of each reporting period, the Company and its subsidiaries perform impairment reviews in respect of the property, premises and equipment and other intangible assets whenever events or changes in circumstances indicate that an asset may be impaired. An impairment loss is recognised when the recoverable amount of an asset, which is the higher of the asset's fair value less costs to sell and its value in use, is less than the carrying amount. In determining value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs to sell, an appropriate valuation model is used. These calculations are corroborated by a valuation model that, based on information available, reflects the amount that the Company and its subsidiaries could obtain from the disposal of the asset in an arm's length transaction between knowledgeable, willing parties, after deducting the costs of disposal.

An impairment loss is recognised in profit or loss. However in cases where property was previously revalued and the revaluation was taken to equity, a part of such impairment is recognised in equity up to the amount of the previous revaluation.

In the assessment of asset impairment if there is any indication that previously recognised impairment losses may no longer exist or may have decreased, the Company and its subsidiaries estimate the asset's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The increased carrying amount of the asset attributable to a reversal of an impairment loss shall not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years.

Such reversal is recognised in profit or loss unless the asset is carried at a revalued amount, in which case the reversal, which exceeds the carrying amount that would have been determined, is treated as a revaluation increase.

5.15 Leasehold rights

Leasehold rights are amortised on the straight-line basis over the lease period.

5.16 Foreign currencies

The consolidated and separate financial statements are presented in Baht, which is also the Company and its subsidiaries' functional currency. Items of each entity included in the consolidated financial statements are measured using the functional currency of that entity.

Transactions in foreign currencies are translated into Baht at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into Baht at the exchange rate ruling at the end of reporting period.

Gains and losses on exchange are included in determining income.

5.17 Convertible debentures

Convertible debentures are classified into liability and equity components and these are presented separately in the statements of financial position. In separately presenting such components, the Company determines the liability component by discounting the stream of future payments of principal and interest at the prevailing market rate. The carrying amount of the equity component was then determined by deducting the liability component from the total carrying value of the convertible debenture.

The liability component is presented at amortised cost until the conversion or maturity of the debentures. The value of the equity component determined upon the issue of the debentures does not change in subsequent periods.

Expenses for issuance debentures separately recorded between liability and equity component and based on the proportion. The expenses related to liability component deducted from convertible debenture - liability component and amortising over the life of the debentures and expenses related to equity component deducted from equity component and did not amortise.

5.18 Employee benefits

Short-term employee benefits

Salaries, wages, bonuses and contributions to the social security fund are recognised as expenses when incurred.

Post-employment benefits

Defined contribution plans

The Company and its subsidiaries and its employees have jointly established a provident fund. The fund is monthly contributed by employees and by the Company and its subsidiaries. The fund's assets are held in a separate trust fund and the Company's and its subsidiaries contributions are recognised as expenses when incurred.

Defined benefit plans

The Company and its subsidiaries have obligations in respect of the severance payments it must make to employees upon retirement under labor law. The Company and its subsidiaries treat these severance payment obligations as a defined benefit plan.

The obligation under the defined benefit plan is determined by a professionally qualified independent actuary based on actuarial techniques, using the projected unit credit method.

Actuarial gains and losses arising from post-employment benefits are recognised immediately in other comprehensive income.

Provisions for vacation

The Company and its subsidiaries have set up provisions for vacation which is calculated in accordance with the Company's policy and formula, taking into consideration the employee's salary, the number of years of service and the unused vacation day.

5.19 Provisions

Provisions are recognised when the Company and its subsidiaries have a present obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

5.20 Income tax

Income tax expense represents the sum of corporate income tax currently payable and deferred tax.

Current tax

Current income tax is provided in the accounts at the amount expected to be paid to the taxation authorities, based on taxable profits determined in accordance with tax legislation.

Deferred tax

Deferred income tax is provided on temporary differences between the tax bases of assets and liabilities and their carrying amounts at the end of each reporting period, using the tax rates enacted at the end of the reporting period.

The Company and its subsidiaries recognise deferred tax liabilities for all taxable temporary differences while they recognise deferred tax assets for all deductible temporary differences and tax losses carried forward to the extent that it is probable that future taxable profit will be available against which such deductible temporary differences and tax losses carried forward can be utilised.

At each reporting date, the Company and its subsidiaries review and reduce the carrying amount of deferred tax assets to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

The Company and its subsidiaries record deferred tax directly to shareholders' equity if the tax relates to items that are recorded directly to shareholders' equity.

5.21 Financial instruments

Financial assets carried on the statement of financial position included cash and cash equivalents, short-term investments, trade and other receivables, short-term loans and long-term loans to related parties, restricted financial institution deposits, and investments. Financial liabilities carried on the statement of financial position included bank overdrafts and short-term loans from financial institutions, trade and other payables, short-term loans from related parties, long-term loans, liabilities under finance leases, debentures and convertible debentures.

The Company and its subsidiaries have no policy to hold any derivative financial instruments for speculative or trading purpose.

5.22 Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between buyer and seller (market participants) at the measurement date. The Company and its subsidiaries apply a quoted market price in an active market to measure their assets and liabilities that are required to be measured at fair value by relevant financial reporting standards. Except in case of no active market of an identical asset or liability or when a quoted market price is not available, the Company and its subsidiaries measure fair value using valuation technique that are appropriate in the circumstances and maximises the use of relevant observable inputs related to assets and liabilities that are required to be measured at fair value.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy into three levels based on categorise of input to be used in fair value measurement as follows:

Level 1 - Use of quoted market prices in an observable active market for such assets or liabilities

Level 2 - Use of other observable inputs for such assets or liabilities, whether directly or indirectly

Level 3 - Use of unobservable inputs such as estimates of future cash flows

At the end of each reporting period, the Company and its subsidiaries determine whether transfers have occurred between levels within the fair value hierarchy for assets and liabilities held at the end of the reporting period that are measured at fair value on a recurring basis.

5.23 Interest rate swap contracts

The net amount of interest to be received from or paid to the counterparty under an interest rate swap contract is recognised as income or expenses on an accrual basis.

6. Significant accounting judgments and estimates

The preparation of financial statements in conformity with generally accepted accounting principles at times requires management to make subjective judgments and estimates regarding matters that are inherently uncertain. These judgments and estimates affect reported amounts and disclosures and actual results could differ from these estimates. Significant judgments and estimates are as follows:

Leases

In determining whether a lease is to be classified as an operating lease or finance lease, the management is required to use judgment regarding whether significant risks and rewards of ownership of the leased asset have been transferred, taking into consideration terms and conditions of the arrangement.

Allowance for doubtful accounts

In determining allowances for doubtful accounts, the management needs to make judgment and estimates based upon, among other things, debt collection experience, the aging profile of outstanding debts and the prevailing economic conditions.

Fair value of financial instruments

In determining the fair value of financial instruments recognised in the statement of financial position that are not actively traded and for which quoted market prices are not readily available, the management exercise judgement, using a variety of valuation techniques and models. The input to these models is taken from observable markets, and includes consideration of credit risk (bank and counterparty, both) liquidity, correlation and longer-term volatility of financial instruments. Change in assumptions about these factors could affect the fair value recognised in the statement of financial position and disclosures of fair value hierarchy.

Property, premises and equipment/Depreciation

In determining depreciation of premises and equipment, the management is required to make estimates of the useful lives and residual values of the Company's and its subsidiaries' premises and equipment and to review estimate useful lives and residual values when there are any changes.

The Company and its subsidiaries measure land at revalued amounts. Fair value from revaluation is determined by independent valuer using market approach. Such valuation is based on certain assumptions and estimates.

In addition, the management is required to review property, premises and equipment for impairment on a periodical basis and record impairment losses in the period when it is determined that their recoverable amount is lower than the carrying amount. This requires judgements regarding forecast of future revenues and expenses relating to the assets subject to the review.

Impairment of equity investments

The Company and its subsidiaries treat available-for-sale investments and other investments as impaired when there has been a significant or prolonged decline in the fair value below their cost or where other objective evidence of impairment exists. The determination of what is "significant" or "prolonged" requires judgement of the management.

Investment properties

The Company and its subsidiaries present investment properties at the fair value estimated by an independent appraiser, and recognise changes in the fair value in profit or loss. The valuation involves certain assumptions and estimates.

Goodwill and intangible assets

The initial recognition and measurement of goodwill and other intangible assets, and subsequent impairment testing, require management to make estimates of cash flows to be generated by the asset or the cash generating unit and to choose a suitable discount rate in order to calculate the present value of those cash flows.

Deferred tax assets

Deferred tax assets are recognised for deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the temporary differences and losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and level of estimate future taxable profits.

Post-employment benefits under defined benefit plans

The obligation under the defined benefit plan is determined based on actuarial techniques. Such determination is made based on various assumptions, including discount rate, future salary increase rate, mortality rate and staff turnover rate.

Litigation

The Company and its subsidiaries have contingent liabilities arising from litigation. The Company's management has used judgment to assess the outcome of the litigation. In cases of loss, the Company and its subsidiaries will record provision for contingent liabilities in their books of account. In cases where it has assessed that no damage will arise from the litigation, the Company and its subsidiaries will not record provision for contingent liabilities at the end of the reporting period.

7. Cash and cash equivalents

Cash and cash equivalents consist of the following:

		(Unit: Thousand Baht)	
	Consolidated financial statements		Separate financial statements
	<u>2015</u>	<u>2014</u>	<u>2015</u> <u>2014</u>
		(Restated)	
Cash and deposits at financial institution	5,028,512	3,585,291	3,617,144 1,862,515
Fixed deposits	500,031	23,077	- -
Total cash and cash equivalents	<u>5,528,543</u>	<u>3,608,368</u>	<u>3,617,144</u> <u>1,862,515</u>

As at 31 December 2015, bank deposits in saving accounts and fixed deposits carried interests between 0.10 and 1.10 percent per annum (2014: between 0.13 and 3.00 percent per annum).

8. Short-term investments

Short-term investments consist of the following:

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Fixed deposits	27,455	294,339	538	-
Mutual funds	826	1,583,279	815	1,583,292
Total short-term investments	<u>28,281</u>	<u>1,877,618</u>	<u>1,353</u>	<u>1,583,292</u>

As at 31 December 2015, bank deposits in fixed deposits carried interests between 0.75 and 1.80 percent per annum (2014: between 1.0 and 3.0 percent per annum).

9. Restricted financial institutions deposits

These represent bank deposits that the Company and its subsidiary companies have placed with banks to secure letters of guarantees issued by the banks on behalf of the Company and its subsidiary companies. These also represent bank deposits have placed with government agencies, state enterprises and private entities to guarantee contractual performance.

10. Trade and other receivables

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(Restated)			
Trade receivables - related parties	12,072	8,913	23,662	16,935
Trade receivables - unrelated parties-net	6,182,436	5,509,084	1,335,013	919,616
Other receivables - related parties	218	28,911	92,413	80,454
Other receivables - unrelated parties	289,617	275,229	18,970	34,767
Total trade and other receivables - net	<u>6,484,343</u>	<u>5,822,137</u>	<u>1,470,058</u>	<u>1,051,772</u>

11. Trade accounts receivable

As at 31 December 2015 and 2014, the aging analysis of the outstanding trade accounts receivable is as follows:

	Consolidated financial statements		(Unit: Thousand Baht) Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
<u>Related parties</u>				
Less than 3 months	11,730	8,381	22,356	16,793
3 - 6 months	316	373	1,254	142
6 - 12 months	9	47	52	-
over 12 months	17	112	-	-
Total trade accounts receivable - related parties	<u>12,072</u>	<u>8,913</u>	<u>23,662</u>	<u>16,935</u>
<u>Unrelated parties</u>				
Less than 3 months	5,219,929	4,616,581	1,090,299	869,391
3 - 6 months	601,096	601,296	164,679	60,593
6 - 12 months	335,000	309,471	104,749	32,177
over 12 months	487,687	413,212	225,426	199,574
Total trade accounts receivable - unrelated parties	<u>6,643,712</u>	<u>5,940,560</u>	<u>1,585,153</u>	<u>1,161,735</u>
Less: Allowance for doubtful accounts	<u>(461,276)</u>	<u>(431,476)</u>	<u>(250,140)</u>	<u>(242,119)</u>
Total trade accounts receivable - unrelated parties - net	<u>6,182,436</u>	<u>5,509,084</u>	<u>1,335,013</u>	<u>919,616</u>
Total trade accounts receivable -net	<u><u>6,194,508</u></u>	<u><u>5,517,997</u></u>	<u><u>1,358,675</u></u>	<u><u>936,551</u></u>

12. Related party transactions

The Company and its subsidiaries had significant business transactions with individuals or related parties, which have been concluded on commercial terms and bases agreed upon between the Company and those related parties. Below is a summary of those transactions.

<u>Transaction</u>	<u>Pricing and lending policy</u>
Revenues from hospital operations and lab services	Based on the price charged to normal customers
Revenues and expenses from consulting and management	Rates as stipulated in agreements
Revenues and costs of sales and purchases of goods and services	Based on the price charged to normal customers
Rental income and rental expenses	Rates as stipulated in agreements
Interest charge of inter-company loans	Interest rates close to that charged by commercial banks
Purchases and sales of assets	Prices are dependent on the condition of assets
Purchases of investments	The same prices as purchases from unrelated parties

The significant intercompany transactions are as follows:

(Unit: Million Baht)				
For the years ended 31 December				
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
		(Restated)		(Restated)
<u>Associated companies</u>				
Revenue from hospital operations and lab services	31.1	22.2	12.1	11.0
Dividend income (Note 14)	-	-	431.0	387.3
Other income	21.2	48.8	-	-
Service cost	4.9	1.1	1.0	-
Other expenses	-	0.1	-	-
<u>Subsidiary companies</u>				
Revenue from hospital operations and lab services	-	-	91.7	70.1
Consulting and management fee income	-	-	628.6	524.1
Interest income	-	-	295.0	247.7
Dividend income (Note 15)	-	-	2,927.6	1,987.3
Other income	-	-	69.6	64.5
Service cost	-	-	819.0	781.9
Consulting and management fee expenses	-	-	238.1	253.4
Other expenses	-	-	82.8	87.2
Interest expenses	-	-	99.4	78.2
Purchase of assets	-	-	-	7.1
<u>Individuals or related companies</u>				
Revenue from hospital operations and lab services	5.5	5.2	2.6	2.1
Dividend income (Note 16)	8.1	0.6	8.1	0.6
Interest income	-	14.3	-	14.3
Gain on sale of asset	-	94.5	-	94.5
Other income	8.7	6.7	8.1	6.5
Service cost	15.0	7.4	3.0	0.8
Other expenses	44.0	55.1	26.3	35.1
Dividend payment	279.1	242.8	279.1	242.8
Purchase of assets	-	4.6	-	-

The outstanding balances of the above transactions as at 31 December 2015 and 2014 have been separately shown in the statement of financial position as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
<u>Trade receivables - related parties (Note 10)</u>				
Associated companies	10,723	7,087	2,225	3,104
Subsidiary companies	-	-	20,824	12,597
Related companies	1,349	1,826	613	1,234
Total trade receivables - related parties	<u>12,072</u>	<u>8,913</u>	<u>23,662</u>	<u>16,935</u>
<u>Dividend receivable - a related party</u>				
An associated company	-	9,100	-	-
Total dividend receivable - a related party	<u>-</u>	<u>9,100</u>	<u>-</u>	<u>-</u>
<u>Other receivables - related parties (Note10)</u>				
Consulting and management fee receivable				
Subsidiary companies	-	-	57,097	46,751
Total	<u>-</u>	<u>-</u>	<u>57,097</u>	<u>46,751</u>
<u>Others</u>				
Associated companies	36	20,181	36	-
Subsidiary companies	-	-	35,116	32,921
Related companies	182	8,730	164	782
Total	<u>218</u>	<u>28,911</u>	<u>35,316</u>	<u>33,703</u>
Total other receivables - related parties	<u>218</u>	<u>28,911</u>	<u>92,413</u>	<u>80,454</u>
<u>Leasehold rights - a related party (restated)</u>				
(included in other non-current assets)				
A related party	46,708	52,800	-	-
Total leasehold rights - a related party	<u>46,708</u>	<u>52,800</u>	<u>-</u>	<u>-</u>
<u>Deposits and long-term prepaid expense - a related party</u>				
(included in other non-current assets)				
Subsidiary company	-	-	2,298	3,528
Total deposits and long-term prepaid expense - related party	<u>-</u>	<u>-</u>	<u>2,298</u>	<u>3,528</u>

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
<u>Trade payables - related parties (Note 23)</u>				
Associated companies	3,070	13,933	429	9
Subsidiary companies	-	-	129,496	138,276
Related companies	2,550	1,804	336	104
Total trade payables - related parties	<u>5,620</u>	<u>15,737</u>	<u>130,261</u>	<u>138,389</u>
<u>Other payables - related parties (Note 23)</u>				
Associated companies	8	1,980	-	-
Subsidiary companies	-	-	82,528	49,902
Related companies	4,435	3,779	1,708	1,746
Total other payables - related parties	<u>4,443</u>	<u>5,759</u>	<u>84,236</u>	<u>51,648</u>
<u>Deposits - related parties</u>				
(included in other non-current liabilities)				
Subsidiary companies	-	-	2,866	1,210
Related companies	765	735	765	735
Total deposits - related parties	<u>765</u>	<u>735</u>	<u>3,631</u>	<u>1,945</u>

Movement of loans to and loans from related parties during the year are summarised as follows:

	(Unit: Thousand Baht)			
	Separate financial statements			
	31 December			31 December
	<u>2014</u>	<u>Increase</u>	<u>Decrease</u>	<u>2015</u>
<u>Short-term loans to related parties</u>				
Subsidiary companies	1,755,709	501,670	(930,440)	1,326,939
Total short-term loans to related parties	<u>1,755,709</u>	<u>501,670</u>	<u>(930,440)</u>	<u>1,326,939</u>
<u>Long-term loans to related parties</u>				
Subsidiary companies	5,341,175	1,256,805	(811,609)	5,786,371
Total long-term loans to related parties	<u>5,341,175</u>	<u>1,256,805</u>	<u>(811,609)</u>	<u>5,786,371</u>
<u>Short-term loans from related parties</u>				
Subsidiary companies	4,703,039	4,390,532	(790,237)	8,303,334
Total short-term loans from related parties	<u>4,703,039</u>	<u>4,390,532</u>	<u>(790,237)</u>	<u>8,303,334</u>

Short-term and long-term loans to related parties and short-term loans from related parties

The Company has entered into agreement to provide short-term loans and long-term loans with terms of 3 - 8 years with its subsidiaries and also obtained short-term loans from its subsidiaries. The loans to related parties bear interest at MLR minus fixed rate per annum and LIBOR plus fixed rate per annum stipulated in the agreement. The loans from related parties bear interest at Fixed Deposit Rate. The interest is payable on a monthly basis while principal is repayable on the basis stipulated in the agreements.

Service and management agreement

The Company

The Company has entered into management service agreements with subsidiary companies. The Company is to receive a monthly management income at a certain percentage of net revenue as stipulated in the agreements.

The Subsidiaries

A subsidiary company has entered into a hospital management agreement with three subsidiary companies. The subsidiary company is to receive management income at a certain percentage of net revenue as stipulated in the agreement.

A subsidiary company has entered into service and management agreements with the Company and subsidiaries which have to pay monthly service and management fees to the subsidiary at the rates stipulated in the agreements.

A subsidiary company has entered into accounting service agreements with the Company and subsidiaries which have to pay monthly service fees to the subsidiary at the rates stipulated in the agreements.

A subsidiary company has entered into information technology management agreements with the Company and subsidiaries which have to pay monthly service fees to the subsidiary at the rate stipulated in the agreements.

A related company has entered into a maintenance and management service agreement with a subsidiary company which has to pay monthly service fee to the related company at the rate stipulated in the agreement.

Long term rental agreement

The Company

In May 2004, a subsidiary company has entered into a three-year agreement to rent land from the Company for use in hospital operations whereby the subsidiary company has to pay a monthly rental fee at the rate stipulated in the agreement. Subsequently, the subsidiary extended the agreement to 30 April 2016.

The Subsidiaries

A subsidiary company has entered into an agreement to rent land from another subsidiary company for construction of a building, with the subsidiary company to pay a monthly rental fee at the rate stipulated in the agreement. The subsidiary then entered into an agreement to rent the building from the subsidiary company for its hospital operations, expiring on 30 April 2017, with the subsidiary to pay a monthly rental at the rate stipulated in the agreement.

Air ambulance service agreement

Subsidiary company

On 1 September 2007, a subsidiary company entered into an air ambulance service agreement with the Company. The agreement is for a period of 3 years from the date the service commenced and is renewable. The agreement stipulates the monthly minimum service fee that the subsidiary company is to earn from the Company. The Company has extended the agreement for 3 years ended on 30 September 2018.

Guarantee obligations with related parties

The Company has guaranteed long-term loan with a financial institution amount of USD 1.1 million (2014: USD 1.7 million) and overdraft facility amounting to USD 1.0 million (2014: USD 1.0 million) for an overseas subsidiary company.

Sales of land not use in operation

In 2013, the Company has entered into agreement to sell land of Baht 399 million with a related party. The Company received interest on the requested postponement the scheduled purchase of the land. In the third quarter of 2014, the Company sold land and transferred the ownership to such related party.

Directors and management's benefits

During the years ended 31 December 2015 and 2014, the Company and its subsidiaries had benefits for their directors and management as below.

	(Unit: Million Baht)			
	Consolidated financial		Separate financial	
	statements		statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Short-term employee benefits	169.3	151.6	169.3	151.6
Post-employment benefits	2.2	2.3	2.2	2.3
Total	<u>171.5</u>	<u>153.9</u>	<u>171.5</u>	<u>153.9</u>

13. Inventories

	(Unit: Thousand Baht)			
	Consolidated financial		Separate financial	
	statements		statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Medicines and medical supplies	1,051,936	808,021	99,743	98,629
Reagent	161,617	121,488	-	-
Supplies and others	75,698	182,981	-	-
Total	<u>1,289,251</u>	<u>1,112,490</u>	<u>99,743</u>	<u>98,629</u>
Less: Provision for deteriorated inventories	<u>(3,482)</u>	<u>(1,677)</u>	<u>(385)</u>	<u>-</u>
Inventories - net	<u>1,285,769</u>	<u>1,110,813</u>	<u>99,358</u>	<u>98,629</u>

14. Investments in associated companies

(Unit: Thousand Baht)

Company's name	Natures of business	Paid-up Capital	% Shareholding		Consolidated financial statements		Separate financial statements	
					Equity Method		Cost Method	
					<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
				(Restated)		(Restated)		(Restated)
<u>Associated companies held by the Company</u>								
Cool & Joy Co., Ltd.	Ceased operation	Baht 5 million	30.00	30.00	1,069	1,069	1,500	1,500
Ramkhamhaeng Hospital Public Co., Ltd.	Hospital	Baht 120 million	38.24	38.24	3,930,146	3,653,933	1,459,801	1,459,801
Udon Pattana (1994) Co., Ltd. (held by the Company at 15.26% and indirectly held by subsidiary at 9.85%)	Hospital	Baht 300 million	25.11	25.11	202,268	198,180	69,952	69,952
Bumrungrad Hospital Public Co., Ltd.	Hospital	Baht 730 million	23.95	23.95	10,608,288	10,164,710	7,497,336	7,497,336
Total investments in associated companies held by the Company							<u>9,028,589</u>	<u>9,028,589</u>
Total investments in associated companies held by the Company and subsidiaries					<u>14,741,771</u>	<u>14,017,892</u>		
<u>Associated companies held by the subsidiary companies</u>								
Sodexo Support Services (Thailand) Co., Ltd.	Management services	Baht 5 million	-	26.00	-	7,134		
Al Ghaith Bangkok Dusit Management Services LLC.	Management services	UAE DIRHAM 0.15 million	30.00	30.00	-	-		
G. Wasupol Co., Ltd.	In process of liquidation	Baht 54 million	25.83	25.83	17,175	157,850		
General Hospital Products Public Co., Ltd. (indirectly held by subsidiaries at 44.67%)	Manufacturer and distributor of medical supplies	Baht 120 million	44.67	-	<u>334,089</u>	<u>-</u>		
Total investments in associated companies held by subsidiary companies					<u>351,264</u>	<u>164,984</u>		
Total investments in associated companies in the consolidated financial statements					<u>15,093,035</u>	<u>14,182,876</u>		

14.1 Additional investments in an associated company

In 2015, Royal Bangkok Healthcare Co., Ltd., a subsidiary company in which the Company has a 100% shareholding, invested in General Hospital Products Public Company Limited, purchasing 5,326,443 shares, representing 44.39% of the paid up capital of such company. The value of the investment is Baht 306.5 million. The total investments in General Hospital Products Public Company Limited, including of shareholding of 0.32% with the investment value of Baht 1.8 million by another subsidiary, totally representing 44.67% of the paid up capital of such company which is indirectly held by the Group. Therefore, General Hospital Products Public Company Limited changed its status to become an associated company.

14.2 Sale of investments held by subsidiary

On 21 August 2015, a meeting of the Board of Directors No. 4/2015 of Samitivej Public Co., Ltd., a subsidiary, passed the resolution to approve First Health Food Co., Ltd., a subsidiary company of Samitivej Public Co., Ltd., to sell investments in Sodexo Support Service (Thailand) Co., Ltd. and investments in Sodexo Healthcare Support Service (Thailand) Co., Ltd. to a company. The subsidiary company sold the investments in November, 2015 at the amount of Baht 112.85 million. Investments in Sodexo Support Service (Thailand) Co., Ltd. is First Health Food Co., Ltd.'s investments in associate with 26 percentage of ownership. In addition, investments in Sodexo Healthcare Support Service (Thailand) Co., Ltd. is First Health Food Co., Ltd.'s investments in subsidiary with 74 percentage of ownership. The amount of investment in associate under equity method and net asset of subsidiary company owned by the subsidiary company on the selling date is Baht 14.55 million and Baht 40.97 million, respectively. The Company had recognised gain from selling these investments amounting to Baht 57.33 million in the consolidated financial statements.

14.3 Details of share of income, comprehensive income and dividend received from the associated companies

Company's name	Consolidated financial statements				(Unit: Thousand Baht) Separate financial statements	
	Share of profit from investments in associates during the year		Share of other comprehensive income from investments in associates during the year		Dividend received during the year	
	2015	2014	2015	2014	2015	2014
<u>Associated companies held by the Company</u>						
Cool & Joy Co., Ltd.	-	-	-	-	-	-
Ramkhamhaeng Hospital Public Co., Ltd.	389,383	386,302	(58,109)	288,707	55,061	55,061
Udon Patana (1994) Co., Ltd.	4,088	6,849	-	-	-	-
Bumrungrad Hospital Public Co., Ltd.	822,895	653,916	4,395	(5,902)	375,928	332,215
<u>Associated companies held by the subsidiary companies</u>						
Sodexo Support Services (Thailand) Co., Ltd.	7,411	9,588	-	-	-	-
Al Ghaith Bangkok Dusit Management Services LLC.	-	-	-	-	-	-
G. Wasupol Co., Ltd.	9,461	9,771	-	-	-	-
General Hospital Products Public Co., Ltd.	25,730	-	-	-	-	-
Total	<u>1,258,968</u>	<u>1,066,426</u>	<u>(53,714)</u>	<u>282,805</u>	<u>430,989</u>	<u>387,276</u>

Fair value of investments in listed associated companies

Fair values as at 31 December 2015 and 2014 of investments in associated companies that are listed on the Stock Exchange of Thailand which were based on the closing price as quoted on the Stock Exchange of Thailand are as follows:

Company's name	(Unit: Thousand Baht) Fair values as at 31 December	
	2015	2014
Ramkhamhaeng Hospital Public Co., Ltd.	9,176,848	9,176,848
Bumrungrad Hospital Public Co., Ltd.	36,893,392	24,653,878
Total	<u>46,070,240</u>	<u>33,830,726</u>

14.4 Below is a summary of financial information of associated companies

(Unit: Million Baht)

Company's name	As at 31 December						For the years ended 31 December			
	Paid-up capital		Total assets		Total liabilities		Total revenues		Net income (loss)	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
<u>Associated companies held by the Company</u>										
Cool & Joy Co., Ltd.	Baht 5 million	Baht 5 million	2.9	2.9	-	-	-	-	-	-
Ramkhamhaeng Hospital Public Co., Ltd.	Baht 120 million	Baht 120 million	11,306.5	10,857.9	3,619.8	3,914.6	3,640.2	3,680.0	1,009.3	999.0
Udon Patana (1994) Co., Ltd.	Baht 300 million	Baht 300 million	1,106.5	1,082.1	314.8	306.7	511.2	502.0	16.3	27.3
Bumrungrad Hospital Public Co., Ltd.	Baht 730 million	Baht 730 million	21,297.5	19,144.7	8,197.0	7,884.7	17,929.4	15,910.5	3,427.5	2,734.8
<u>Associated companies held by the subsidiary companies</u>										
Sodexo Support Services (Thailand) Co., Ltd.	-	Baht 5 million	-	163.3	-	135.9	378.3	465.7	28.5	36.9
Al Ghaith Bangkok Dusit Management Services LLC.	UAE DIRHAM	UAE DIRHAM	-	-	-	-	-	-	-	-
	0.15 million	0.15 million								
G. Wasupol Co., Ltd.	Baht 54 million	Baht 54 million	72.8	296.6	6.9	43.6	1,396.0	132.2	1,209.1	37.8
General Hospital Products Public Co., Ltd.	Baht 120 million	Baht 60 million	1,534.8	1,536.1	884.9	1,238.9	871.0	791.2	55.5	16.2

Share of income from investment in two associated companies which are listed company on the Stock Exchange of Thailand for the year ended 31 December 2015 of Baht 1,212.3 million (2014: two associated companies Baht 1,040.2 million) representing 96 percent (2014: 97 percent) of total share of income from all associated companies were calculated based on audited financial statements of those companies.

15. Investments in subsidiary companies

(Unit: Thousand Baht)								
Company's name	Nature of business	Paid-up Capital	Separate financial statements					
			% Shareholding		Investments -		Dividend received	
			2015	2014	cost method		during the year	
					2015	2014	2015	2014
					(Restated)			
Samitivej Public Co., Ltd.	Hospital	Baht 1,000 million	95.76	95.76	1,639,071	1,639,071	1,244,927	526,700
Bangkok Hospital Hatyai Co., Ltd.	Hospital	Baht 500 million	98.81	98.80	574,612	574,535	123,500	98,800
Bangkok Phuket Hospital Co., Ltd.	Hospital	Baht 500 million	99.69	99.69	610,246	610,174	249,215	49,843
BNH Medical Center Co., Ltd.	Hospital	Baht 586 million	91.48	91.48	602,657	602,657	80,429	160,857
Bangkok Phrapradaeng Hospital Co., Ltd.	Hospital	Baht 105 million	84.00	84.00	101,868	101,868	-	-
Bangkok Pattaya Hospital Co., Ltd.	Hospital	Baht 280 million	97.27	97.27	708,993	708,966	190,640	490,218
Bangkok Rayong Hospital Co., Ltd.	Hospital	Baht 400 million	100.00	100.00	415,020	415,020	120,000	-
Bangkok Samui Hospital Co., Ltd.	Hospital	Baht 150 million	100.00	100.00	150,000	150,000	75,000	67,500
Bangkok Trat Hospital Co., Ltd.	Hospital	Baht 250 million	99.76	99.76	245,889	245,889	17,457	17,457
Wattanavej Co., Ltd.	Hospital	Baht 180 million	99.69	99.69	450,643	450,643	125,615	107,670
Bangkok Ratchasima Hospital Co., Ltd.	Hospital	Baht 300 million	91.36	91.36	934,348	934,348	54,814	40,923
National Healthcare Systems Co., Ltd. (held by the Company at 74.02% and indirectly held by subsidiaries at 24.66%.	Central Lab	Baht 75 million	74.02	74.02	56,768	56,768	66,622	-
Bio Molecular Laboratories (Thailand) Co., Ltd.	Central Lab	Baht 10 million	95.00	95.00	9,502	9,502	23,750	19,000
Angkor Pisith Co., Ltd.	Hospital	USD 10 million	80.00	80.00	287,840	287,840	-	-
Phnom Penh Medical Services Co., Ltd.	Hospital	USD 25 million	100.00	100.00	813,220	813,220	-	-
Royal Rattanak Medical Services Co., Ltd.	Ceased operation	Riel 26,000 million	70.00	70.00	154,063	154,063	-	-
B.D.M.S. International Medical Services Co., Ltd.	Not yet operate	Riel 9,200 million	100.00	100.00	94,208	94,208	-	-

(Unit: Thousand Baht)

Company's name	Nature of business	Paid-up Capital	% Shareholding		Separate financial statements			
					Investments -		Dividend received	
					cost method		during the year	
			<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
					(Restated)			
BDMS Accounting Co., Ltd.	Accounting service	Baht 30 million	100.00	100.00	30,000	30,000	-	-
Bangkok Health Insurance Public Co., Ltd.	Health insurance	Baht 200 million	99.97	99.97	142,027	142,027	-	-
Royal Bangkok Healthcare Co., Ltd.	Investment	Baht 1,086 million	100.00	100.00	1,086,000	736,000	-	-
Greenline Synergy Co., Ltd.	Technology and information service	Baht 200 million	100.00	100.00	200,000	200,000	-	-
Bangkok Hospital Kao Yai Co., Ltd.	Not yet operate	Baht 70 million	100.00	100.00	70,000	70,000	-	-
BDMS Training Co., Ltd.	Training business	Baht 1 million	100.00	100.00	1,000	1,000	-	-
Prasit Patana Public Co., Ltd.	Investment	Baht 1,108 million	98.56	98.52	9,260,264	9,256,115	349,435	185,604
Paolo Medic Co., Ltd.	Hospital	Baht 600 million	100.00	100.00	3,222,872	2,922,872	-	60,000
Paolo Samutprakarn Co., Ltd.	Hospital	Baht 42 million	93.64	93.61	1,737,638	1,737,239	137,611	94,200
Siam Medical Co., Ltd.	Hospital	Baht 100 million	85.71	85.71	939,775	939,775	68,571	68,571
Thai Medical Center Public Co., Ltd.	Hospital	Baht 201 million	99.76	99.76	887,131	887,131	-	-
Bangkok Premier Life Insurance Broker Co., Ltd.	Life insurance broker	Baht 20 million	100.00	100.00	20,000	20,000	-	-
Bangkok Hospital Chiangmai Co., Ltd.	Hospital	Baht 1,000 million	100.00	100.00	1,000,000	1,000,000	-	-
Bangkok Hospital Udon Co., Ltd.	Hospital	Baht 500 million	100.00	100.00	499,930	499,930	-	-
Bangkok Khon Kaen Hospital Co., Ltd.	Hospital	Baht 800 million	100.00	100.00	800,000	800,000	-	-
The Medicpharma Co., Ltd.	Production and distribution of medicines	Baht 42.86 million	87.05	86.89	551,318	214,900	-	-

(Unit: Thousand Baht)

Company's name	Nature of business	Paid-up Capital	Separate financial statements					
			% Shareholding		Investments -		Dividend received	
					cost method		during the year	
			<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
						(Restated)		
Thonburi Medical Center Public Co., Ltd. (held by the Company at 29.01% and indirectly held by subsidiary at 29.02%)	Hospital	Baht 193.8 million	29.01	29.01	327,802	327,802	-	-
Bangkok Hospital Surat Co., Ltd.	Not yet operate	Baht 165million	100.00	100.00	165,000	90,000	-	-
BDMS Inter Pte. Ltd.	Investment	USD 100,000	100.00	100.00	3,381	1,217	-	-
N Health Asia Pte. Ltd.	Investment	USD 2 million	100.00	100.00	65,310	65,310	-	-
Samitivej Chonburi Co., Ltd.	Hospital	Baht 600 million	100.00	100.00	600,000	600,000	-	-
Bangkok Hospital Phitsanulok Co., Ltd.	Hospital	Baht 600 million	100.00	100.00	600,000	600,000	-	-
Bangkok Hospital Sanamchan Co., Ltd.	Hospital	Baht 3,655 million	100.00	100.00	3,655,000	3,655,000	-	-
Bangkok Phuket International Hospital Co., Ltd.	Hospital	Baht 3,610 million	100.00	100.00	3,610,000	3,610,000	-	-
Bangkok Save Drug Co., Ltd.	Investment	Baht 450 million	100.00	100.00	450,000	405,000	-	-
S.R. Property Investment Co., Ltd.	Real estate	Riel 20 million	49.00	49.00	101	101	-	-
Siem Reap Land Investment Co., Ltd.	Real estate	Riel 20 million	49.00	49.00	101	101	-	-
Phnom Penh First Property Co., Ltd.	Real estate	Riel 20 million	49.00	49.00	88	88	-	-
Bangkok Helicopter Services Co., Ltd.	Air transportation services	Baht 100 million	49.00	49.00	50,859	50,859	-	-

(Unit: Thousand Baht)								
Company's name	Nature of business	Paid-up Capital	% Shareholding		Separate financial statements			
					Investments -		Dividend received	
			2015	2014	cost method		during the year	
					2015	2014	2015	2014
					(Restated)			
Bangkok Hospital Chiangrai Co., Ltd.	Not yet operate	Baht 100 million	100.00	-	100,000	-	-	-
Bangkok Hospital Muangraj Co., Ltd.	Hospital	Baht 1,300 million	100.00	-	1,300,000	-	-	-
Total investments in subsidiary companies					39,224,545	36,711,239	2,927,586	1,987,343
Less: Allowance for impairment of investments					(154,062)	(154,062)		
Total investments in subsidiary companies - net					39,070,483	36,557,177		

15.1 Investments in subsidiary companies which the Company and its subsidiary companies previously held

Royal Bangkok Healthcare Co., Ltd.

On 25 February 2015, the Extraordinary General Meeting of shareholders No. 1/2015 of Royal Bangkok Healthcare Co., Ltd passed the resolution to approve the increase of its registered capital from Baht 736 million to Baht 1,086 million through the increase in capital of additional 35 million ordinary shares with a par value of Baht 10 each. The Company already paid for the additional shares totalling Baht 350 million in the second quarter of 2015.

Paolo Samutprakarn Co., Ltd.

In 2015, the Company purchased additional investment totalling Baht 0.4 million in Paolo Samutprakarn Co., Ltd. As a result, the Company's shareholding in that company increased to 93.64 percent.

Paolo Medic Co., Ltd.

On 26 March 2015, the Annual General Meeting of the shareholders No. 1/2015 of Paolo Medic Co., Ltd. passed the resolution to approve the increase of its registered capital from Baht 300 million to Baht 600 million through the increase in capital of additional 30 million ordinary shares with a par value of Baht 10 each. The Company already invested Baht 10 each in the additional shares totalling Baht 300 million in the second quarter of 2015.

The Medicpharma Co., Ltd.

On 27 March 2015, the 2015 Annual General Meeting of shareholders of The Medicpharma Co., Ltd. passed the resolution to approve the increase of its registered capital from Baht 21.43 million to Baht 42.86 million through the increase in capital of 2.14 million additional ordinary shares with a par value of Baht 10 each. The Company already invested Baht 180 each in 1.87 million additional shares totalling Baht 336.42 million in the second quarter of 2015. As a result, the Company's shareholding in that company increased to 87.05 percent.

Prasit Patana Public Co., Ltd.

In 2015, the Company purchased additional investment totalling Baht 4.1 million in Prasit Patana Public Co., Ltd. As a result, the Company's shareholding in that company increased to 98.56 percent.

Bangkok Hospital Surat Co., Ltd.

On 24 April 2015, a meeting of the Board of Directors of Bangkok Hospital Surat Co., Ltd. approved the call up of additional share capital of Baht 75 million. As a result, the subsidiary had an issued and paid up share capital of Baht 165 million. The Company already paid for the additional shares in the fourth quarter of 2015.

BDMS Inter Pte. Ltd

On 9 November 2015, the Board of Directors of BDMS Inter Pte. Ltd approved to increase the share capital from USD 40,000 to USD 100,000. In the fourth quarter of 2015, the Company acquired all of the new ordinary shares in order to maintain its shareholding.

Bangkok Save Drug Co., Ltd. and Save Drug Center Co., Ltd.

On 24 August 2015, a meeting of the Board of Directors of Bangkok Save Drug Co., Ltd. approved the call up of additional share capital of Baht 45 million. As a result, the subsidiary had an issued and paid up share capital of Baht 450 million (45 million ordinary shares at Baht 10 each). The Company already paid for the additional shares in September 2015.

On 10 September 2015, the extraordinary General Meeting No.1/2015 of the shareholders of Save Drug Center Co., Ltd. passed a resolution approving an increase in the registered capital, from Baht 230 million to Baht 440 million, through the issue of 21 million additional ordinary shares with a par value of Baht 10 each. Bangkok Save Drug Co., Ltd. paid up additional share capital of Baht 147 million in September 2015.

N Health Asia Pte. Ltd. and N Health Myanmar Co., Ltd.

On 28 August 2013, a meeting of the Board of Directors of the Company approved the establishment of N Health Myanmar Co., Ltd., the Company's newly established subsidiary company in Republic of the Union of Myanmar with a registered share capital of USD 500,000. The Company has indirectly invested in this new subsidiary company through N Health Asia Pte. Ltd., a subsidiary. The Company indirectly holds 60 percent interest in this subsidiary. The subsidiary is in the process of registering its establishment.

Samitivej Public Co., Ltd. and its subsidiaries.

On 4 September 2013, a meeting of the Board of Directors of SV Holding Co., Ltd., a subsidiary of Samitivej Public Co., Ltd., approved the establishment of a new subsidiary, namely Samitivej International Co., Ltd., located in Republic of the Union of Myanmar with a registered share capital of USD 1,250,000 which is 80% held by SV Holding Co., Ltd. The subsidiary has registered its establishment in the third quarter of 2014. As at 31 December 2015, the subsidiary had paid-up capital of USD 660,767.

On 25 September 2015, Extraordinary General Meeting of shareholders No. 1/2015 of SV Holding Co., Ltd. passed the resolution to approve the increase of its registered capital from Baht 40 million to Baht 80 million through the increase in capital of 400,000 additional ordinary shares with a par value of Baht 100 each. Samitivej Public Co., Ltd. already invested in the additional shares totalling Baht 40 million and SV Holding Co., Ltd. has registered its increasing share capital in October 2015.

15.2 Investments in new subsidiary companies

Bangkok Hospital Chiangrai Co., Ltd.

On 30 June 2015, the Board of Directors of the Company approved the establishment of a new subsidiary company, Bangkok Hospital Chiangrai Co., Ltd. with a registered share capital of Baht 100 million, comprising 10 million shares with Baht 10 par value each. The Company holds 100 percent interest in this company. In August 2015, Bangkok Hospital Chiangrai Co., Ltd. completely registered its' establishment and has Baht 100 million paid-up capital.

Bangkok Hospital Muangraj Co., Ltd. and the entire business transfer of G. Wasupol Co., Ltd.

On 30 June 2015, the Board of Directors of the Company approved the establishment of a new subsidiary company, Bangkok Hospital Muangraj Co., Ltd. with a registered share capital of Baht 1,300 million, comprising 130 million shares with Baht 10 par value each. The Company holds 100 percent interest in this company. The Board of Directors of the Company has also approved that Bangkok Hospital Muangraj Co., Ltd. could enter into the entire business transfer of G. Wasupol Co., Ltd.

On 1 September 2015, Bangkok Hospital Muangraj Co., Ltd. has entered into the entire business transfer of G. Wasupol Co., Ltd., making cash payment for the entire business transfer of Baht 1,427 million with transferring of liabilities.

The fair values of assets and liabilities as at acquisition dates are as follows:

	(Unit: Thousand Baht)
Cash and cash equivalents	67,651
Trade and other receivables	28,051
Short-term loan	608
Inventories	9,189
Other current assets	589
Available-for-sale investments	6,450
Property, premises and equipment	489,414
Other non-current assets	2
Trade and other payables	(13,182)
Other current liabilities	(19,842)
Provision for long-term employee benefits	(10,296)
Deferred tax liabilities	(63,923)
Fair value of net assets	494,711
Fair value of the subsidiary company's existing shareholding in G. Wasupol Co., Ltd., before acquisitions*	(368,689)
Fair value of net assets acquired	126,022
Add: Goodwill	932,319
Consideration paid (Cash paid for investments) - Cash paid for entire business transfer of Baht 1,427,030 thousand deducted subsidiary company's existing shareholding in G. Wasupol Co., Ltd., of Baht 368,689 thousand)	1,058,341
Less: Cash and cash equivalents of subsidiary company	(67,651)
Net cash paid for acquisition of subsidiary company	990,690

* The Company realised gain from the remeasurement of subsidiary company's previously held shareholding of 25.836 percent in G. Wasupol Co., Ltd. to fair value in the consolidated statement of income by Baht 209 million, under the caption "gain on fair value adjustment of investments".

15.3 Summarised financial information that based on amounts before inter-company elimination of subsidiaries that have material non-controlling interest.

Regarding the preparation of consolidated financial statements of the Company and its subsidiaries, there are 5 subsidiary companies having material non-controlling interest since the Company has 49 to 60 percentage of ownership over these subsidiary companies.

The summary of financial information before elimination transactions of the subsidiary company having material non-controlling interest, based on the Company's percentage of ownership in the subsidiary companies, is on the followings:

(Unit: Million Baht)

Company's name	As at 31 December						For the year ended 31 December			
	Paid-up capital		Total assets		Total liabilities		Total revenues		Net income	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Thonburi Medical Center Public Co., Ltd.	193.8	193.8	656.5	645.6	181.4	130.0	450.4	354.6	(43.6)	(32.5)
S.R. Property Investment Co., Ltd.	0.2	0.2	79.4	72.5	72.0	66.5	0.8	0.7	0.8	0.7
Siem Reap Land Investment Co., Ltd.	0.2	0.2	72.3	66.0	65.9	60.9	0.7	0.7	0.7	0.6
Phnom Penh First Property Co., Ltd.	0.2	0.2	166.1	151.7	152.6	140.9	1.6	1.5	1.6	1.5
Bangkok Helicopter Services Co., Ltd.	100.0	100.0	158.9	183.1	81.0	119.0	65.4	70.2	13.9	0.5

16. Other long-term investments

(Unit: Thousand Baht)

Consolidated and separate
financial statements

Dividend income during
the years

Company's name	Nature of business	Paid-up capital (Million Baht)	% share holding	Investment (cost)		Dividend income during the years	
				2015	2014	2015	2014
<u>Investments held by the Company</u>							
<u>Available-for-sale investments</u>							
<u>Investments in listed securities</u>							
Thai Military Bank Public Co., Ltd.	Bank	41,562	-	1,770	1,770	5	4
Aikchol Hospital Public Co., Ltd.	Hospital	150	0.20	350	350	195	192
Bangkok Chain Hospital Public Co., Ltd.	Hospital	2,494	1.50	269,829	269,829	4,500	4,875
				271,949	271,949	4,700	5,071
Surplus on changes in value of available-for-sale investments				78,121	33,087	-	-
Investments in listed securities				350,070	305,036	4,700	5,071
<u>Investments in related companies</u>							
Bangkok Airways Public Co., Ltd.	Airline	2,100	0.85	39,466	39,466	8,057	-
X-Ray Computer Urupong Co., Ltd.	X-ray lab	100	4.09	-	4,520	-	613
				39,466	43,986	8,057	613
Surplus on changes in value of available-for-sale investments				372,363	309,693	-	-
Investments in related companies				411,829	353,679	8,057	613

(Unit: Thousand Baht)							
						Consolidated and separate	
						financial statements	
Company's name	Nature of business	Paid-up capital (Million Baht)	% share holding	Investment (cost)		Dividend income during the years	
				2015	2014	2015	2014
<u>Investments in unrelated companies</u>							
Thai Longstay Management Co., Ltd.	Travel business	100	0.53	531	531	-	-
Superior Biotech Holding Co., Ltd.	Investment	53	7.58	5,000	5,000	200	200
X-Ray Computer Urupong Co., Ltd.	X-ray lab	100	4.09	4,520	-	613	-
Investments in unrelated companies				10,051	5,531	813	200
Total other long-term investments in the separate financial statements				771,950	664,246	13,570	5,884

						(Unit: Thousand Baht)	
						Consolidated and separate	
						financial statements	
Company's name	Nature of business	Paid-up capital (Million Baht)	% share holding	Investment (cost)		Dividend income during	
				2015	2014	2015	2014
<u>Investment held by the subsidiary companies</u>							
<u>Available-for-sale investments</u>							
Investments in investment unit				10,000	10,000	-	-
Surplus on changes in value of available-for-sale investments				1,225	1,060	-	-
Investments in investment unit				11,225	11,060	-	-
<u>Investment in listed securities</u>							
Mahachai Hospital Public Company Limited	Hospital	160	4.28	143,724	143,724	2,053	-
Kiatnakin Bank Public Company Limited	Bank	8,468	0.02	6,450	-	200	-
				150,174	143,724	2,253	
Loss on changes in value of available-for-sale investments				(29,997)	(19,848)	-	-
Investments in listed securities				120,177	123,876	2,253	-
Investment in Government Saving Bank bonds				-	25,000	-	-

In the second quarter of 2015, the subsidiary redeemed the matured investment in Government Saving Bank bonds amounting to Baht 25 million.

						(Unit: Thousand Baht)	
						Consolidated and separate financial statements	
Company's name	Nature of business	Paid-up capital (Million Baht)	% share holding	Investment (cost)		Dividend income during the years	
				2015	2014	2015	2014
<u>Investments in unrelated companies</u>							
Thai Herbal Products Co., Ltd.	Sales of herbal products	80	0.60	290	290	48	143
Prasitthirat Co., Ltd.	Educational institution known as “Rangsit university”	150	33.33	107,192	107,192	2,000	2,500
Asia Laboratories Center Limited	Central lab	5	8.00	400	400	40	28
Kendall Gammatron Limited	Trading of medical supplies	120	5.10	8,000	8,000	-	-
General Hospital Products Public Co.,Ltd.	Manufacturer and distributor of medical supplies	120	0.44	-	1,178	-	-
Black Brain Health, LLC.	Manufacturer and distributor of complementary medicine	USD 1.38 million	8.31	17,975	-	-	-
Investments in unrelated companies				133,857	117,060	2,088	2,671
<u>Investments in ordinary shares (ceased operations)</u>							
Phyathai 4 Hospital (Petchaburi Road) Co., Ltd.	Adjudged bankrupt	328	89.79		-	-	-
Klass - V Co., Ltd.	Adjudged bankrupt	250	89.66		-	-	-
Phuket Paradise Co., Ltd.	Adjudged bankrupt	409	72.26		-	-	-
Phyathai Herbs Co., Ltd.	In process of liquidation	196	63.64	42,889	42,889	-	-
Phuket Hospital Public Co., Ltd.	Hospital	358	19.08	-	-	-	-
Phuket International Hospital Co., Ltd.	In process of liquidation	195	6.15	29,552	29,552	-	205,938
				72,441	72,441	-	205,968
Less : Allowance for impairment of investment				(24,493)	(7,000)	-	-
Investments in ordinary shares (ceased operations) - net				47,948	65,441	-	205,938
Total other long-term investments - net in the consolidated financial statements				1,085,157	1,006,683	17,911	214,523

The Company and its subsidiaries recorded the changes in the gain in value of available-for-sale investment in the consolidated financial statements of Baht 78 million (net of deferred tax liabilities of Baht 20 million) and in the separate financial statements of Baht 86 million (net of deferred tax liabilities of Baht 21 million) and presented in the statements of comprehensive income under “Gain (loss) on change in value of available-for-sale investments”.

General Hospital Products Public Company Limited

In the first quarter of 2015, General Hospital Products Public Company Limited had changed its status from other company to become an associated company as mentioned in Note 14.

Black Brain Health, LLC.

On 20 April 2015, a Meeting of the Board of Directors No. 4/2015 of Royal Bangkok Healthcare Company Limited which is the Company’s subsidiary company has approved the investment in 173,695 common shares or 8.31 percent in Black Brain Health, LLC., which locates in The United States of America at USD 2.879 each totaling USD 500,000.

Prasitthirat Company Limited

A subsidiary company has 33.33 percentage of shareholding in Prasitthirat Company Limited but has not classified it as investment in associated company because the subsidiary company has no power to participate in the financial and operating policy decisions of that company and other shareholders are major shareholders of that company.

Investments in ordinary shares (ceased operations)

A subsidiary company has investments in companies that have ceased their operations but has not classified them as investments in subsidiary companies because the subsidiary company has no power to control such companies.

17. Investment properties

(Unit: Thousand Baht)

	Consolidated financial statements			Separate financial statements		
	Land	Building	Total	Land	Building	Total
31 December 2013	35,445	225,254	260,699	289,104	225,254	514,358
Purchase	-	187	187	-	187	187
Transfer from property, premises and equipment	-	2,064	2,064	-	2,064	2,064
Gain on revalue of assets	-	2,500	2,500	-	2,500	2,500
31 December 2014	35,445	230,005	265,450	289,104	230,005	519,109
Purchase	-	2,129	2,129	-	2,129	2,129
Transfer from property, premises and equipment	-	8,189	8,189	-	-	-
Gain on revalue of assets	-	9,000	9,000	-	9,000	9,000
31 December 2015	35,445	249,323	284,768	289,104	241,134	530,238

The investment properties of the Company and its subsidiaries consist of land and building for rent. The fair value of land has been determined based on valuations performed by an accredited independent valuer, using the Market approach. The fair value of building for rent has been determined based on income approach.

Key assumptions used in the valuation of building for rent are summarised below:

	Consolidated financial statements	Separate financial statements	Result to fair value where as an increase in assumption value
Vacancy rate (%)	100	100	Increase in fair value
Discount rate (%)	12	12	Decrease in fair value

18. Property, premises and equipment

(Unit: Thousand Baht)

Consolidated financial statements							
Assets which are stated at cost or reappraised value	Assets which are stated at cost						Total
	Land and land improvement	Building and improvement	Medical tools, machine, helicopter and equipment	Structure equipment, furniture, fixture and office equipment	Vehicles	Building under construction and medical tools and equipment under installation	
Cost/reappraised value							
31 December 2013 - As previously reported	11,813,092	28,680,348	15,005,460	7,850,616	770,872	3,174,355	67,294,743
Cumulative effect of change in accounting policy	288,760	-	237,222	825	25	-	526,832
Reclassification	-	(6,430)	6,430	-	-	-	-
31 December 2013 - As restated and reclassified	12,101,852	28,673,918	15,249,112	7,851,441	770,897	3,174,355	67,821,575
Increase from acquisitions	1,228,583	1,788,724	554,599	306,374	24,416	180,687	4,083,383
Increase from revaluation	879,371	-	-	-	-	-	879,371
Purchases	353,350	1,440,756	2,168,553	1,893,194	61,810	1,767,700	7,685,363
Transfer in / (Transfer out)	34,663	1,987,965	306,638	370,096	2,568	(2,740,256)	(38,326)
Disposals/Written-off	-	(42,459)	(194,898)	(78,711)	(35,897)	(4,750)	(356,715)
Translation adjustment	1,313	4,296	2,624	2,614	28	7	10,882
31 December 2014 - As restated	14,599,132	33,853,200	18,086,628	10,345,008	823,822	2,377,743	80,085,533
Increase from acquisitions	164,581	504,957	87,410	57,947	6,513	26,462	847,870
Increase from revaluation	3,183,399	-	-	-	-	-	3,183,399
Purchases	865,606	639,927	1,828,991	908,046	98,183	2,096,258	6,437,011
Transfer in / (Transfer out)	20,416	1,121,829	183,234	505,105	1,811	(1,835,526)	(3,131)
Decrease from sales of investment in subsidiary	-	-	-	(71,234)	(6,612)	-	(77,846)
Disposals/Written-off	(1,767)	(51,038)	(1,096,204)	(1,112,237)	(68,640)	(1,538)	(2,331,424)
Translation adjustment	27,505	78,114	17,183	52,015	588	60	175,465
31 December 2015	18,858,872	36,146,989	19,107,242	10,684,650	855,665	2,663,459	88,316,877

(Unit: Thousand Baht)

Consolidated financial statements

	Assets which are stated at cost or reappraised value	Assets which are stated at cost					
	Land and land improvement	Building and improvement	Medical tools, machine, helicopter and equipment	Structure equipment, furniture, fixture and office equipment	Vehicles	Building under construction and medical tools and equipment under installation	Total
<u>Accumulated depreciation</u>							
31 December 2013 - As							
previously reported	26,454	13,139,303	9,352,096	5,335,612	542,538	-	28,396,003
Cumulative effect of change in accounting policy	-	-	82,970	731	25	-	83,726
Reclassification	-	(12)	12	-	-	-	-
31 December 2013 - As							
restated and reclassified	26,454	13,139,291	9,435,078	5,336,343	542,563	-	28,479,729
Increase from acquisitions	10,937	682,742	424,892	199,840	20,615	-	1,339,026
Depreciation for the year	3,769	1,383,106	1,384,265	677,159	73,362	-	3,521,661
Transfer in /							
(Transfer out)	-	(903)	71,368	(70,910)	-	-	(445)
Disposals/Written-off	-	(35,393)	(180,448)	(69,761)	(35,796)	-	(321,398)
Translation adjustment	-	579	163	439	24	-	1,205
31 December 2014 - As							
restated	41,160	15,169,422	11,135,318	6,073,110	600,768	-	33,019,778
Increase from acquisitions	8,865	228,455	69,918	45,628	5,589	-	358,455
Depreciation for the year	7,262	1,578,092	1,637,745	883,150	74,784	-	4,181,033
Transfer in /							
(Transfer out)	-	(58,202)	47,259	(3,632)	-	-	(14,575)
Decrease from sales of investment in subsidiary	-	-	-	(47,055)	(6,655)	-	(53,710)
Disposals/Written-off	(167)	(50,063)	(1,059,305)	(1,102,937)	(66,796)	-	(2,279,268)
Translation adjustment	-	7,148	5,320	9,144	449	-	22,061
31 December 2015	57,120	16,874,852	11,836,255	5,857,408	608,139	-	35,233,774

(Unit: Thousand Baht)

Consolidated financial statements (continued)

Consolidated financial statements (continued)							
Assets which are stated at cost or reappraised value	Assets which are stated at cost						
	Land and land improvement	Building and improvement	Medical tools, machine, helicopter and equipment	Structure equipment, furniture, fixture and office equipment	Vehicles	Building under construction and medical tools and equipment under installation	Total
<u>Allowance for impairment of fixed assets</u>							
31 December 2013	4,869	18,890	-	-	-	-	23,759
Increase from acquisition	-	11,777	-	-	-	-	11,777
Impairment loss	-	79,306	12,811	1,373	1,471	-	94,961
31 December 2014	4,869	109,973	12,811	1,373	1,471	-	130,497
Impairment loss	-	2,700	-	-	-	-	2,700
31 December 2015	4,869	112,673	12,811	1,373	1,471	-	133,197
<u>Net book value</u>							
31 December 2014	14,553,103	18,573,805	6,938,499	4,270,525	221,583	2,377,743	46,935,258
31 December 2015	18,796,883	19,159,464	7,258,176	4,825,869	246,055	2,663,459	52,949,906
Depreciation charged included in income statement for the year							
2014 (Baht 2,816 million included in cost of hospital operations, sales and services, and the balance in administrative expenses)							3,521,661
2015 (Baht 3,348 million included in cost of hospital operations, sales and services, and the balance in administrative expenses)							4,181,033

(Unit: Thousand Baht)

Separate financial statements							
Assets which are stated at cost or reappraised value	Assets which are stated at cost						
	Land and land improvement	Building and improvement	Medical tools, machine and equipment	Structure equipment, furniture, fixture and office equipment	Vehicles	Building under construction and medical tools and equipment under installation	Total
Cost/reappraised value							
31 December 2013	1,815,100	5,121,348	3,750,951	1,908,322	190,139	412,103	13,197,963
Purchases	68,337	270,841	409,454	270,838	25,513	75,865	1,120,848
Transfer in / (Transfer out)	2,196	257,075	10,437	76,482	1,898	(364,848)	(16,760)
Disposals/Written-off	-	(1,635)	(29,625)	(10,570)	(12,274)	(40)	(54,144)
31 December 2014	1,885,633	5,647,629	4,141,217	2,245,072	205,276	123,080	14,247,907
Purchases	694,492	106,867	173,600	163,326	24,999	275,964	1,439,248
Transfer in / (Transfer out)	476	68,415	7,656	32,274	564	(108,597)	788
Disposals/Written-off	-	(19,906)	(650,102)	(964,462)	(13,655)	-	(1,648,125)
31 December 2015	2,580,601	5,803,005	3,672,371	1,476,210	217,184	290,447	14,039,818
Accumulated depreciation							
31 December 2013	21	2,308,232	2,515,874	1,308,709	130,560	-	6,263,396
Depreciation for the year	265	239,264	267,877	115,429	19,542	-	642,377
Transfer in / (Transfer out)	-	(883)	-	439	-	-	(444)
Disposals/Written-off	-	(317)	(21,622)	(9,999)	(12,274)	-	(44,212)
31 December 2014	286	2,546,296	2,762,129	1,414,578	137,828	-	6,861,117
Depreciation for the year	300	265,253	307,013	153,971	20,708	-	747,245
Transfer in / (Transfer out)	-	2,132	(10,925)	370	-	-	(8,423)
Disposals/Written-off	-	(15,414)	(641,620)	(962,771)	(13,231)	-	(1,633,036)
31 December 2015	586	2,798,267	2,416,597	606,148	145,305	-	5,966,903
Allowance for impairment of fixed assets							
31 December 2014	-	-	-	-	-	-	-
Impairment loss	-	2,700	-	-	-	-	2,700
31 December 2015	-	2,700	-	-	-	-	2,700
Net book value							
31 December 2014	1,885,347	3,101,333	1,379,088	830,494	67,448	123,080	7,386,790
31 December 2015	2,580,015	3,002,038	1,255,774	870,062	71,879	290,447	8,070,215
Depreciation charged included in income statement for the year							
2014 (Baht 551 million included in cost of hospital operations, sales and services, and the balance in administrative expenses)							642,377
2015 (Baht 630 million included in cost of hospital operations, sales and services, and the balance in administrative expenses)							747,245

In 2015, eight subsidiary companies have recorded appraisal result which engaged an independent appraiser to appraise all of their land using the market approach. The fair values of the revalued land in consolidated financial statements amount of Baht 6,742.6 million which increased from the book values of Baht 2,541.3 Million (net of deferred tax liabilities of Baht 642.1 million). The subsidiaries recorded the increase amount as “Revaluation surplus on land” in the other components of shareholders' equity.

In 2014, four subsidiary companies have recorded appraisal result which engaged an independent appraiser to appraise all of their land using the market approach. The fair values of the revalued land in consolidated financial statements amount of Baht 3,683 million which increased from the book values of Baht 703 Million (net of deferred tax liabilities of Baht 176 million). The subsidiaries recorded the increase amount as “Revaluation surplus on land” in the other components of shareholders' equity.

The revaluation surplus can neither be offset against deficit nor used for dividend payment.

If the Company and its subsidiaries recorded land at cost, net book value as at 31 December 2015 and 2014 would have been as follows:

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Net book value (at cost):		
As of 31 December 2015	10,861,087	2,045,083
As of 31 December 2014	9,857,172	1,351,476

As at 31 December 2015, the Company and its subsidiaries have medical tools, equipment and vehicles under finance lease agreements with net book values amounting to Baht 99.9 million and Baht 16.7 million in the separate financial statements (2014: Baht 115.9 million and Baht 26.6 million in the separate financial statements).

As at 31 December 2015, the Company and its subsidiaries have certain building improvement, medical tools, equipment and vehicles which have been fully depreciated but are still in use. The original cost of those assets amounted to approximately Baht 14,857.1 million and Baht 3,518.9 million in the separate financial statement (2014: Baht 15,141.7 million and Baht 4,297.3 million in the separate financial statements).

19. Land not used in operations

Land not used in operations as at 31 December 2015 and 2014 consisted of:

	Consolidated		(Unit: Thousand Baht)	
	financial statements		Separate	
	2015	2014	2015	2014
<u>Land at historical cost</u>				
Balance brought forward	120,225	347,752	119,898	347,425
Disposal	-	(227,527)	-	(227,527)
Balance carry forward	120,225	120,225	119,898	119,898
<u>Revaluation surplus</u>				
Balance brought forward	177,802	254,975	177,802	254,975
Reversal revaluation surplus	-	(77,173)	-	(77,173)
Balance carry forward	177,802	177,802	177,802	177,802
<u>Allowance for impairment</u>	(719)	(719)	(719)	(719)
Total	297,308	297,308	296,981	296,981

The cumulative capitalised interest on loans recorded as a portion of cost of land not used in operations amounted to approximately Baht 29 million (2014: Baht 29 million).

20. Intangible assets

Intangible assets, as at 31 December 2015 and 2014, which are computer software and commercial rights, are as follows:

	(Unit: Thousand Baht)	
	Consolidated financial statements (Restated)	Separate financial statements
Cost		
As at 31 December 2013 - As previously reported	1,414,875	421,344
Cumulative effect of change in accounting policy	13	-
As at 31 December 2013 - As restated	1,414,888	421,344
Increase from acquisitions	194,536	-
Purchases	186,541	72,158
Transfer in	12,855	13,593
Disposals/written-off	(23,007)	(17,035)
Translation adjustment	(2,167)	-
As at 31 December 2014 - After restated	1,783,646	490,060
Increase from acquisitions	34	-
Purchases	360,811	135,542
Transfer in/(Transfer out)	(10,252)	(4,719)
Decrease from sales of investment in subsidiary	(6,630)	-
Disposals/written-off	(30,809)	(10,137)
Translation adjustment	63	-
As at 31 December 2015	2,096,863	610,746
Accumulated amortisation		
As at 31 December 2013 - As previously reported	759,955	129,821
Cumulative effect of change in accounting policy	13	-
As at 31 December 2013 - As restated	759,968	129,821
Increase from acquisitions	8,449	-
Amortisation for the year	158,493	49,749
Transfer in	328	-
Disposals/written-off	(3,558)	-
Translation adjustment	(1,401)	-
As at 31 December 2014	922,279	179,570
Increase from acquisitions	34	-
Amortisation for the year	167,505	56,105
Transfer in	6,128	-
Decrease from sales of investment in subsidiary	(5,684)	-
Disposals/written-off	(30,187)	(10,072)
Translation adjustment	60	-
As at 31 December 2015	1,060,135	225,603
Net book value		
As at 31 December 2014	861,367	310,490
As at 31 December 2015	1,036,728	385,143

21. Leasehold rights

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
		(Restated)		
Cost	926,662	922,393	444,881	444,881
Less: Accumulated amortisation	(256,485)	(222,018)	(82,459)	(65,319)
Book value - net	<u>670,177</u>	<u>700,375</u>	<u>362,422</u>	<u>379,562</u>
Amortisation for the year	<u>38,162</u>	<u>36,209</u>	<u>17,140</u>	<u>16,897</u>

A reconciliation of the net book value of leasehold rights for the years 2015 and 2014 is presented below.

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Net book value at beginning of year				
- As previously reported	968,607	967,951	379,562	396,459
Cumulative effect of change in accounting policy	(268,232)	(269,933)	-	-
Net book value at beginning of year				
- As restated	700,375	698,018	379,562	396,459
Increase from acquisition	-	29,813	-	-
Purchases	3,000	19,453	-	-
Less: amortisation	(38,162)	(36,209)	(17,140)	(16,897)
Translation adjustment	4,964	(10,700)	-	-
Net book value at end of year	<u>670,177</u>	<u>700,375</u>	<u>362,422</u>	<u>379,562</u>

22. Bank overdrafts and short-term loans from financial institutions

As at 31 December 2015, the Company and its subsidiaries have bank overdraft facilities with banks of Baht 1,010 million and USD 1 million (2014: Baht 1,193 million and USD 1 million) and in separate financial statements of Baht 860 million (2014: Baht 860 million). The facilities carry interest rate at MOR for Baht currency facilities and LIBOR plus fixed rate for US currency facilities.

23. Trade and other payables

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
		(Restated)		
Trade payables - related parties	5,620	15,737	130,261	138,389
Trade payables - unrelated parties	2,971,644	2,853,990	383,176	358,912
Other payables - related parties	4,443	5,759	84,236	51,648
Other payables - unrelated parties	1,435,544	948,652	615,939	305,695
Accounts payable - construction and retention	517,500	564,598	75,271	73,114
Total trade and other payables	<u>4,934,751</u>	<u>4,388,736</u>	<u>1,288,883</u>	<u>927,758</u>

24. Long-term loans from financial institutions

	(Unit: Thousand Baht)	
	Consolidated	Separate
	financial	financial
	statements	statements
	(Restated)	
Balance as at 31 December 2014 - As previously reported	10,903,971	10,844,607
Cumulative effect of change in accounting policy	60,010	-
Balance as at 31 December 2014 - As restated	10,963,981	10,844,607
Increase	1,000	-
Less: Repayment during the year	(1,585,964)	(1,537,681)
Unrealised loss on foreign exchange	62,812	62,812
Translation adjustment	4,384	-
Balance as at 31 December 2015	9,446,213	9,369,738
Less: Current portion of long-term loans from financial institutions	(1,708,224)	(1,672,206)
Long-term loans from financial institutions - net of current portion	<u>7,737,989</u>	<u>7,697,532</u>

The Company

- a) In 2008, the Company entered into a 10-year loan agreement with a bank granting the credit facilities of Baht 3,438 million. The loan carries interest at the Fixed Deposit Rate plus fixed rate per annum as stipulated in the agreement with interest and principal payable on a monthly basis. This loan agreement includes a condition that the Company and its subsidiaries may not mortgage any assets and also certain covenants which the Company and its subsidiaries must comply. The outstanding balance of this loan as at 31 December 2015 was Baht 744.9 million (2014: Baht 1,088.7 million).
- b) In November 2011, the Company entered into a 7 years and 6 months loan agreement with a financial institution granting credit facilities of Baht 3,000 million carrying interest at the rate of six-month Fixed Deposit Rate plus fixed rates per annum as stipulated in the agreement. The interest is repayable on a monthly basis and the principal is repayable on a quarterly basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of Baht 1,519 million (2014: Baht 1,919 million).
- c) In January 2012, the Company entered into a 8 years and 6 months loan agreement with a financial institution granting credit facilities of Baht 586 million carrying interest at the rate of six-month Fixed Deposit Rate plus fixed rates per annum as stipulated in the agreement. The interest and principal are repayable on a monthly basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of Baht 401 million (2014: Baht 470.6 million).
- d) In June 2012, the Company entered into a 7 years and 6 months loan agreement with a financial institution granting credit facilities of Baht 1,766 million carrying interest at the rate of six-month Fixed Deposit Rate plus fixed rates per annum as stipulated in the agreement. The interest is repayable on a monthly basis and principal is repayable on a quarterly basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of Baht 1,078.4 million (2014: Baht 1,348.0 million).
- e) In July 2012, the Company entered into a 5-year loan agreement with a financial institution amounting to Baht 2,500 million carrying interest at the fixed rate per annum as stipulated in the agreement. The interest is repayable on a semi-annually basis and principal is repayable at the end of loan period. As at 31 December 2015, this loan has outstanding balance of Baht 2,500 million (2014: Baht 2,500 million).

- f) In February 2014, the Company entered into a 7-year loan agreement with a financial institution granting credit facilities of USD 20 million carrying interest at the rate of LIBOR plus fixed rates for the first year and at the fixed rates per annum as stipulated in the agreement. The interest is repayable on a quarterly basis and the principal is repayable on a semi-annually basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of USD 20.0 million or equivalent to Baht 725.1 Million (2014: USD 20.0 million or equivalent to Baht 662.3 million).
- g) In April 2014, the Company entered into a 5-year loan agreement with a financial institution granting credit facilities of Baht 1,000 million carrying interest at the rate of three-month BIBOR plus fixed rates per annum as stipulated in the agreement. The interest and principal are repayable on a monthly basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of Baht 833.3 million (2014: Baht 1,000.0 million).
- h) In May 2013, the Company entered into a 7-year loan agreement with a financial institution granting credit facilities of Baht 2,000 million. In the second quarter of 2014, the Company drawn down the loan totaling Baht 2,000 million. The loan carries interest at the rate of six-month fixed deposit rate plus fixed rates per annum as stipulated in the agreement. The interest is repayable on a monthly basis and principal is repayable on a semi-annually basis according to a condition as stipulated in the agreement. As at 31 December 2015, this loan has outstanding balance of Baht 1,568.0 million (2014: Baht 1,856.0 million).

The subsidiaries

- a) In 2007 and 2008, Angkor Pisith Co., Ltd., a subsidiary company, entered into a 7 years and 10 months loan agreement with a foreign financial institution granting credit facilities of USD 4 million. The loan bears interest at the rate of LIBOR plus a fixed rate per annum. The interest is repayable on a monthly basis and the principal is repayable on a quarterly basis according to a condition as stipulated in the agreement. This loan is guaranteed by the Company. As at 31 December 2015, this loan has outstanding balance of USD 1.1 million or equivalent to Baht 38.0 million. (2014: USD 1.7 million or equivalent to Baht 57.1 million).
- b) In 2008, Bangkok Ratchasima Hospital Co., Ltd., a subsidiary company, entered into a 7 - year loan agreement with a financial institution. The credit facilities were Baht 20 million. The loan bears interest at fixed rate per annum. The interest and principal are repayable on a monthly basis according to a condition as stipulated in the agreement. As at 31 December 2014, the subsidiary company had outstanding balance of Baht 2.3 million and the loan was fully repaid in August 2015.

- c) In 2007, Bangkok Helicopter Services Co., Ltd., a subsidiary company entered into a 10-year long-term loan agreement with a financial institution granting credit facilities of Baht 200 million and revised the credit limit to Baht 190 million in 2010 which the interest and principal repayment is payable on a monthly basis carrying interest of MLR minus fixed rates as stipulated in the agreement. A subsidiary company transferred the claim in service expense on claims transfer agreement to the financial institution for loan guarantee as above. As at 31 December 2015, this loan has outstanding balance of Baht 37.5 million (2014: Baht 60.0 million).
- d) In 2015, Thonburi Medical Centre Public Company Limited, a subsidiary company entered into a 8-year loan agreement with a bank granting the credit facilities of Baht 300 million. The loan carries interest at the rate of MLR minus fixed rates per annum as stipulated in the agreement with interest and principal payable on a monthly basis. As at 31 December 2015, the subsidiary company has outstanding balance of Baht 1.0 million.

The Company's and its subsidiaries' loan agreements contain certain covenants which the Company and its subsidiaries must comply such as financial ratios.

25. Liabilities under finance lease agreements

As at 31 December 2015 and 2014, liabilities under finance lease agreements are as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	2015	2014	2015	2014
Liabilities under finance lease agreements	108,364	169,770	17,284	27,412
Less: Deferred interest expenses	(4,213)	(9,029)	(526)	(1,290)
Total	104,151	160,741	16,758	26,122
Less: Current portion of liabilities under finance lease agreements	(57,206)	(59,338)	(10,230)	(10,718)
Liabilities under finance lease agreements - net of current portion	46,945	101,403	6,528	15,404

As at 31 December 2015 and 2014, the Company and its subsidiaries have future minimum lease payments which required under the finance lease agreements as follows:

	(Unit: Thousand Baht)		
	As at 31 December 2015		
	Consolidated financial statements		
	Less than 1		
	year	1-5 years	Total
Future minimum finance lease payments	60,138	48,226	108,364
Deferred interest expenses	(2,932)	(1,281)	(4,213)
Present value of future minimum finance lease payments	57,206	46,945	104,151

	(Unit: Thousand Baht)		
	As at 31 December 2014		
	Consolidated financial statements		
	Less than 1		
	year	1-5 years	Total
Future minimum finance lease payments	63,849	105,921	169,770
Deferred interest expenses	(4,511)	(4,518)	(9,029)
Present value of future minimum finance lease payments	59,338	101,403	160,741

	(Unit: Thousand Baht)		
	As at 31 December 2015		
	Separate financial statements		
	Less than 1		
	year	1-5 years	Total
Future minimum finance lease payments	10,628	6,656	17,284
Deferred interest expenses	(398)	(128)	(526)
Present value of future minimum finance lease payments	10,230	6,528	16,758

	(Unit: Thousand Baht)		
	As at 31 December 2014		
	Separate financial statements		
	Less than 1		
	year	1-5 years	Total
Future minimum finance lease payments	11,480	15,932	27,412
Deferred interest expenses	(762)	(528)	(1,290)
Present value of future minimum finance lease payments	10,718	15,404	26,122

The Company and its subsidiaries have finance lease agreements with various leasing companies to rent medical tools, equipment, and vehicles for use in their operations. Installments are due on a monthly basis over 32 - 60 months and at the end of the agreements.

26. Debentures

Movements of debentures net from debenture expenses and amortisation of expenses during the years ended 31 December 2015 and 2014 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated /Separate financial statements	
	<u>2015</u>	<u>2014</u>
Balance as at beginning of year	11,091,987	14,059,235
Debentures issued during the year	2,000,000	-
Redemption of debentures during the year	(2,500,000)	(2,970,000)
Debenture expenses	(2,585)	-
Amortisation of debenture expenses	1,575	2,752
Balance as at end of year	10,590,977	11,091,987
Less: Current portion of debentures	(999,836)	(2,499,843)
Debentures - net of current portion	<u>9,591,141</u>	<u>8,592,144</u>

On 4 June 2009, the Company had issued unsecured, name registered and unsubordinated debentures for the total number of 3,000,000 units, at the price of Baht 1,000 per unit, totaling Baht 3,000 million. These debentures are divided into two tranches: the 5-year debentures for the amount of Baht 2,000 million at the coupon rate of 4.80% per annum and the 7-year debentures for the amount of Baht 1,000 million at the coupon rate of 5.35% per annum with interest payable every six-month. Up to 31 December 2014, the Company had repurchased such debentures for amount of 30,000 units, totaling Baht 30 million. The Company had redeemed the 5-year debentures for the amount of Baht 1,970 million in the second quarter of 2014.

On 3 March 2011, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 2,500,000 units, at the price of Baht 1,000 per unit, totaling Baht 2,500 million. These debentures are 4-year debentures at the coupon rate of 3.99% per annum with interest payable every six-month. The Company had redeemed such debentures in the first quarter of 2015.

On 29 March 2011, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 1,000,000 units, at the price of Baht 1,000 per unit, totaling Baht 1,000 million. These debentures are 3-year debentures at the coupon rate of 3.78% per annum with interest payable every six-month. The Company had redeemed such debentures in the first quarter of 2014.

In August 2012, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 600,000 units, at the price of Baht 1,000 per unit, totaling Baht 600 million. These debentures are 10-year debentures at the coupon rate of 4.5% per annum with interest payable every six-month.

On 14 March 2013, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 4,000,000 units, at the price of Baht 1,000 per unit, totaling Baht 4,000 million. This debenture is 10-year debentures at the coupon rate of 4.63% per annum with interest payable every six-month. On 4 April 2014 and 15 October 2014, the Company entered into an interest rate swap contract for the above debentures totaling Baht 4,000 million with a financial institution as described in Note 40.1.

On 10 May 2013, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 3,000,000 units, at the price of Baht 1,000 per unit, totaling Baht 3,000 million. These debentures are divided into two tranches: the 7-year debentures for the number of 2,000,000 units at the coupon rate of 4.19% per annum and the 10-year debentures for the number of 1,000,000 units at the coupon rate of 4.39% per annum with interest payable every six-month.

On 25 June 2015, the Company had issued unsecured, name registered and unsubordinated debentures without a debentureholders' representative debenture for the total number of 2,000,000 units, at the price of Baht 1,000 per unit, totalling Baht 2,000 million. This debenture is 10-year debentures at the coupon rate of 3.95% per annum with interest payable every six-month. The Company entered into an interest rate swap contract for the above debentures totalling Baht 2,000 million with a financial institution as described in Note 40.1.

Debenture agreement contains certain covenants which the Company must comply with such as financial ratios, payment of dividend, assets dispositions, etc.

Fair values of the above debentures, which were the latest price as at 31 December 2015, were between Baht 1,014 per unit and Baht 1,098 per unit.

27. Convertible debentures

On 5 August 2014, the Extraordinary General Meeting of Shareholders' No. 1/2014 of the Company has approved for the issue and offer of the convertible debentures in the amount not exceeding Baht 10,000 million or an equivalent in other currencies and the Meeting has approved to increase its registered capital to support the conversion of the convertible debentures.

On 18 September 2014, the Company has issued the convertible debentures to the foreign investors (except the investors in the United States of America). Key terms and conditions of the convertible debentures are as the following:

Type of Debentures	Unsecured and unsubordinated convertible debentures
Maturity	5 years, commencing from the issue date
Issue Size	Baht 10,000 million
Currency	THB-Denominated, USD-Settled
Maturity Date	18 September 2019
Put Option	At 18 September 2017 equal to 106.152% of the principal amount
Call Option	At any time after 18 March 2017, if the closing price of the Company's shares is at least 130% of the applicable Early Redemption Amount, divided by the effective Conversion Ratio
Coupon	Zero
Redemption Price	110.462% of principal amount
Conversion Price	Baht 21.045 per one newly issued ordinary share
Outstanding Balance	
as at 31 December 2015	Baht 10,000 million

Convertible debentures agreement contains obligations and certain limitations which the Company must comply with, as specified in the offering circular of the bonds. On 19 September 2014, the convertible debentures were listed on the Singapore Exchange Securities Trading Limited.

Thai Accounting Standard No. 107 "Financial Instruments: Disclosure and Presentation", requires the issuer of convertible debentures to present the debentures' liability and equity components separately in the statement of financial position. Therefore, upon issuing the convertible debentures, the Company separated these components, determining the liability component by discounting the stream of future payments of principal and interest at the prevailing market rate. The carrying amount of the equity component was then determined by deducting the liability component from the total carrying value of the convertible debenture.

The liability component is presented at amortised cost until the conversion or maturity of the debentures. The value of the equity component determined upon the issue of the debentures does not change in subsequent periods.

Fair value of the above convertible debenture, which was the latest price as at 31 December 2015, was 108.766 percent per unit.

28. Provision for long-term employee benefits

Provision for long-term employee benefits, which is compensations on employees' retirement, was as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(Restated)			
Defined benefit obligation at beginning of year	1,356,593	1,204,104	245,985	238,374
Increase from acquisitions	10,296	50,181	-	-
Current service cost	124,049	115,987	21,770	21,557
Interest cost	51,027	46,356	8,704	8,312
Actuarial (gain) loss arising from				
Demographic assumption change	(45,005)	-	3,646	-
Financial assumption change	25,388	-	502	-
Experience adjustments	54,500	-	75,737	-
Benefits paid during the year	(34,365)	(60,035)	(7,565)	(22,258)
Decrease from sales of investment in subsidiary	(12,910)	-	-	-
Defined benefit obligation at end of year	<u>1,529,573</u>	<u>1,356,593</u>	<u>348,779</u>	<u>245,985</u>

Long-term employee benefit expenses included in the profit or loss were as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(Restated)			
Current service cost	124,049	115,987	21,770	21,557
Interest cost	51,027	46,356	8,704	8,312
Total expense recognised in profit or loss	<u>175,076</u>	<u>162,343</u>	<u>30,474</u>	<u>29,869</u>
Line items under which such expenses are included in profit or loss				
Cost of hospital operations, sales and services	98,410	89,163	11,616	10,905
Administrative expenses	76,666	73,623	18,858	18,964

The Company and its subsidiaries expect to pay Baht 188.1 million of long-term employee benefits during the next year (Separate financial statements: Baht 99.5 million) (2014: Baht 36.9 million, separate financial statements: Baht 18.8 million).

As at 31 December 2015, the weighted average duration of the liabilities for long-term employee benefit is 18 years (Separate financial statements: 18 years) (2014: 19 years, separate financial statements: 19 years).

Principal actuarial assumptions at the valuation date were as follows:

	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(% per annum)		(% per annum)	
Discount rate	3.1 - 3.2	3.7 - 4.1	3.1	4.1
Future salary increase rate (depending on age of employee)	5.0	3.0 - 7.5	5.0	6.0

The result of sensitivity analysis for significant assumptions that affect the present value of the long-term employee benefit obligation as at 31 December 2015 are summarised below:

	(Unit: Million Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	Increase 1%	Decrease 1%	Increase 1%	Decrease 1%
Discount rate	(156.1)	162.8	(27.5)	28.1
Salary increase rate	169.9	(165.9)	27.2	(27.3)
	Increase 20%	Decrease 20%	Increase 20%	Decrease 20%
Turnover rate	(141.2)	145.5	(29.2)	30.4

29. Share capital

On 18 April 2014, the Annual General Meeting 2014 of the Company's shareholders has approved the following resolutions;

1. Approved the change in the par value of the Company's ordinary shares from Baht 1 per share to Baht 0.10 per share, resulting in the increase of the number of the Company's ordinary shares from 1,700,004,771 shares to 17,000,047,710 shares. The proportionate shareholdings of existing shareholders will remain unchanged.
2. Approved the reduction of the Company's registered capital in the amount of Baht 150,909,117 from the current registered capital of Baht 1,700,004,771 to the new registered capital of Baht 1,549,095,654 by cancelling its 1,509,091,170 unissued ordinary shares at par value of Baht 0.10 per share.
3. Approved the increase of the Company's registered capital under the General Mandate in the amount of Baht 154,909,564 from the current registered capital of Baht 1,549,095,654 to the new registered capital of Baht 1,704,005,218, by issuing 1,549,095,640 new ordinary shares at par value of Baht 0.10 per share and approved the allocation of the newly issued ordinary shares.

The registration of the change in par value of the Company's ordinary shares and the reduction and the increase of the Company's registered capital was completed in April 2014. As a result, the number of the Company's ordinary shares increased to 17,040,052,180 shares, at par value of Baht 0.10 per share, and the Company has registered capital of Baht 1,704,005,218.

On 5 August 2014, the Extraordinary General Meeting of the Company's shareholders No.1/2014 has approved the following resolutions;

1. Cancellation of the increase in the registered capital of the Company and the allocation of 1,549,095,640 ordinary shares, at a par value of Baht 0.10 per share, under the general mandate as previously approved by the 2014 Annual General Meeting of the Company's shareholders held on 18 April 2014. Reduction of the registered capital of the Company by the amount of Baht 154,909,564 from the existing registered capital of Baht 1,704,005,218 to Baht 1,549,095,654, by cancelling 1,549,095,640 authorised but unissued shares, at a par value of Baht 0.10 per share.
2. Approved the increase in the registered capital of the Company by the amount of Baht 100,691,217.40 from the existing registered capital of Baht 1,549,095,654 to Baht 1,649,786,871.40 by issuing 1,006,912,174 newly issued ordinary shares at a par value of Baht 0.10 per share, divided into (a) newly issued ordinary shares to support the conversion of the convertible debentures in the amount not exceeding 542,183,478 shares and (b) newly issued ordinary shares under the general mandate in the amount not exceeding 464,728,696 shares in which 1) up to 232,364,348 newly issued ordinary shares is to be offered on a public offering basis and 2) up to 232,364,348 newly issued ordinary shares is to be offered on a private placement basis. The allocation of the newly issued ordinary shares pursuant to item 1) or 2) or both shall not, in aggregate, exceed 1.5 percent of the Company's paid-up capital as the date on which the Board of Directors resolved the capital increase, or totaling not exceeding 232,364,348 shares.

The registration of the change in the Company's registered capital was completed in August 2014. As a result, the number of the Company's ordinary shares decreased to 16,497,868,714 shares, at par value of Baht 0.10 per share, and the Company has registered capital of Baht 1,649,786,871.40.

30. Dividend

Dividend	Approved by	Total dividend (Million Baht)	Dividend per share (Baht)
Final dividend for 2013	Annual General Meeting of the shareholders on 18 April 2014	3,098	2.00
Total 2014 dividend		3,098	2.00

The Company paid such dividend in May 2014.

Dividend	Approved by	Total dividend (Million Baht)	Dividend per share (Baht)
Final dividend for 2014	Annual General Meeting of the shareholders on 17 April 2015	3,563	0.23
Total 2015 dividend		3,563	0.23

The Company paid such dividend in May 2015.

31. Statutory reserve

Pursuant to Section 116 of the Public Limited Companies Act B.E. 2535, the Company is required to set aside to a statutory reserve at least 5 percent of its net profit after deducting accumulated deficit brought forward (if any), until the reserve reaches 10 percent of the registered capital. The statutory reserve is not available for dividend distribution.

32. Expenses by nature

Significant expenses by nature for the years ended 31 December 2015 and 2014 are as follows:

	(Unit: Million Baht)			
	Consolidated financial statements		Separate financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(Restated)			
Employee expenses	14,885.2	12,892.9	3,146.9	2,724.1
Doctor fee	13,218.9	12,136.8	2,760.3	2,625.0
Cost of drugs and supplies	8,416.5	7,827.4	1,783.2	1,707.0
Depreciation and amortisation expenses	4,386.7	3,716.4	820.5	709.0
Advertising and public relation expenses	729.9	533.1	324.4	200.0
Rental expenses	718.9	562.1	111.2	110.1

33. Income tax

Income tax of the Company and its subsidiaries are made up as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the years ended		For the years ended	
	31 December		31 December	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
	(Restated)			
Current income tax:				
Current income tax charge	1,927,749	1,680,917	340,825	209,184
Adjustments in respect of current				
income tax of previous year	11,968	(7,795)	7,024	(1,821)
Deferred tax:				
Relating to origination and reversal of				
temporary differences	(75,846)	(2,167)	(35,937)	8,744
Income tax reported in the income				
statements	<u>1,863,871</u>	<u>1,670,955</u>	<u>311,912</u>	<u>216,107</u>

The amounts of income tax relating to each component of other comprehensive income (loss) are as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the years ended		For the years ended	
	31 December		31 December	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Deferred tax relating to actuarial loss	6,977	-	15,977	-
Deferred tax relating to gain on				
change in value of available-for-				
sale investments	(19,544)	(72,452)	(21,541)	(76,374)
Deferred tax relating to gain on				
revaluation of land	(642,122)	(175,874)	-	-
Income tax expenses charged				
directly to other comprehensive				
income	<u>(654,689)</u>	<u>(248,326)</u>	<u>(5,564)</u>	<u>(76,374)</u>

Reconciliation between income tax and the product of accounting profit multiplied by the applicable tax rate is presented below.

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	For the years ended		For the years ended	
	31 December		31 December	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
		(Restated)		
Accounting profit before tax	<u>10,095,378</u>	<u>9,342,231</u>	<u>4,764,895</u>	<u>3,485,546</u>
Applicable tax rate	20%	20%	20%	20%
Accounting profit before tax multiplied by applicable tax rate	2,019,076	1,868,446	952,979	697,109
Adjustments in respect of current income tax of previous year	11,968	(7,795)	7,024	(1,821)
Effects of:				
Promotional privileges	(77,567)	(84,933)	(40,311)	(37,578)
Dividend income not subject to tax	(1,791)	(21,452)	(674,416)	(475,980)
Tax loss not utilised	103,038	88,767	-	-
Gain on fair value adjustment of investment	(41,750)	-	-	-
Share of income from investments in associated companies	(251,794)	(213,285)	-	-
Non-deductible expenses and others	114,629	52,789	68,125	35,818
Additional expense deductions allowed	(11,938)	(11,582)	(1,489)	(1,441)
Total	<u>(167,173)</u>	<u>(189,696)</u>	<u>(648,091)</u>	<u>(479,181)</u>
Income tax reported in the income statements	<u>1,863,871</u>	<u>1,670,955</u>	<u>311,912</u>	<u>216,107</u>
Effective income tax rates	<u>18.46%</u>	<u>17.89%</u>	<u>6.55%</u>	<u>6.20%</u>

The components of deferred tax assets and deferred tax liabilities are as follows:

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	As at 31 December 2015	As at 31 December 2014	As at 31 December 2015	As at 31 December 2014
Deferred tax assets				
Allowance for doubtful accounts	92,255	86,295	50,028	48,424
Allowance for diminution in value of inventories	696	335	77	-
Allowance for asset impairment	17,702	15,425	30,812	30,812
Allowance for impairment for premises and equipment	2,515	-	540	-
Accrued expense and other provision	67,513	34,093	45,392	12,726
Provision for long-term employee benefits	305,915	270,995	69,756	49,197
Others	1,820	(8,433)	-	-
Total	488,416	398,710	196,605	141,159
Deferred tax liabilities				
Accumulated depreciation - plant and equipment	202,586	166,989	53,163	43,837
Amortisation of expense for debentures, convertible debentures and loan	25,332	32,925	25,332	32,925
Gain on fair value adjustment of investment properties	7,214	5,414	57,267	55,467
Gain on re-measuring available-for-sale investments	90,502	68,768	90,097	68,556
Revaluation surplus on land and building	2,648,471	1,968,408	172,324	172,324
Total	2,974,105	2,242,504	398,183	373,109
Deferred tax liabilities - net	2,485,689	1,843,794	201,578	231,950

As at 31 December 2015, the subsidiary companies have unused tax losses totaling Baht 1,260.3 million (2014: 805.8 million), on which deferred tax assets have not been recognised as there are uncertain political and economic future which affect the utilisation of unused tax losses.

Details of expiry date of unused tax loss of subsidiaries are summarised as below:

	(Unit: Million Baht)	
	<u>2015</u>	<u>2014</u>
31 December 2015	-	60.7
31 December 2016	28.8	28.8
31 December 2017	74.8	74.8
31 December 2018	197.7	197.7
31 December 2019	443.8	443.8
31 December 2020	515.2	-
	<u>1,260.3</u>	<u>805.8</u>

34. Earnings per share

Basic earnings per share is determined by dividing profit for the year attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the year. The number of ordinary shares is adjusted in proportion to the change in the number of shares as a result of the change in par value from Baht 1 per share to Baht 0.1 per share as described in Note 29 to the financial statements. The number of ordinary shares is adjusted as if the changes in number of shares and par value had occurred at the beginning of the earliest period reported.

	For the years ended 31 December			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Profit for the year (Baht)	7,917,473,723	7,393,522,539	4,452,982,985	3,269,439,419
Number of ordinary shares after reflecting				
the resulting change in par value (shares)	15,490,956,540	15,490,956,540	15,490,956,540	15,490,956,540
Earnings per share (Baht/share)	0.51	0.48	0.29	0.21

Diluted earnings per share

No disclosure of diluted earnings per share is required for year of 2015 after the issue of convertible debentures (as described in Note 27) since the calculated earnings per share assuming the conversion of all convertible debentures to ordinary shares is antidilutive.

35. Long-term lease agreements

The Company

The Company has entered into a land rental agreement for hospital building for a period of 20 years from 26 February 2004 to 25 February 2024. The rental fee for the first 17 months is Baht 200,000 per month and will be increased by the rate as agreed in the agreement. The rental for the last 3 years will be Baht 560,000 per month.

The Company has entered into a land rental agreement for car parking lot for a period of 6 years from 1 September 2012 to 31 August 2018. The rental fee for the first 3 years is Baht 205,000 per month and the last 3 years is Baht 235,000 per month.

The Company has entered into a land rental agreement for construction of an OPD building for a period of 30 years from 28 September 2004 to 27 September 2034. The first payment date is 10 October 2005 at the rental fee of Baht 50,000 per month and this fee is to be increased every 3 years. The rate will be increased by 10% of the latest rental of every 3 years.

The Company has entered into a land rental agreement for a period of 30 years from 1 January 2006 to 31 December 2036 and the rental is paid on a monthly basis. The first payment date is 5 January 2006 and rental to be paid at Baht 30,000 per month and from 1 January 2027 onward at Baht 100,000 per month.

The Company has entered into an agreement to construct a hospital building on land owned by a government authority. The condition of the agreement states that upon completion of the building construction, the Company has to transfer the ownership over such building to that authority. After the authority accepts such transfer, in 2006 the Company entered into another land and hospital building rental agreement with that government authority. The agreement will cover a period of 30 years after the signing date of the agreement and the Company is obliged to pay rental on a yearly basis. The rental fee for the first 5 years is Baht 492,676 per year and this fee is to be increased every 5 years. The rental for the last 5 years will thus be Baht 990,943 per year.

The Company has entered into a land rental agreement for a period of 30 years from 18 March 2011 to 17 March 2041 and the rental is paid on a monthly basis with no rental for the first 3 months. The first payment date is 18 July 2011 and rental to be paid at Baht 100,000 per month and this fee is to be increased every 3 years. The rate will be increased by 10% of the latest rental of every 3 years.

The Company has entered into rental agreements with a company to operate medical clinic in a building for a period of 3 years from 28 September 2013 to 27 September 2016. The Company has to pay fee at the fixed rate and the rate stipulated in the agreement, of monthly gross operating revenue before deducted any expenses or the minimum fee stipulated in agreement whichever is higher.

The Company has entered into a land and building agreement to operate hospital business and related services for a period of 30 years from 5 April 2013 to 4 April 2043. The Company has to pay rental fee on a yearly basis at fixed rate of Baht 16,449,525 per year and leasehold right of Baht 300 million on the first date of agreement. The leasehold right was fully paid.

The Company has entered into a land and building agreement to operate medical clinic in a building for a period of 3 years from 1 February 2014 to 31 January 2017. The rental fee is Baht 260,000 per month. The Company already cancelled the agreement in 2016.

Samitivej Public Company Limited

The subsidiary company has entered into a rental agreement for a parking building dated 10 September 2003, for 30 years, effective from 8 December 2004. The total rental fee is Baht 155 million. The subsidiary company is committed to pay Baht 39 million as prepaid rental as per the schedule. The remaining rental fee will be paid on a monthly basis. In addition, the subsidiary company has entered into a service agreement with the same company for providing of services in the parking building for 30 years totaling Baht 103 million.

The subsidiary company has entered into a rental agreement with a company to operate medical clinic in a building for a period of 5 years from 28 May 2010. The contract period has been extended to 31 August 2016. The subsidiary company has to pay fee at the rate stipulated in the agreement, of monthly gross operating revenue before deducted any expenses or the minimum fee stipulated in agreement whichever is higher.

BNH Medical Center Co., Ltd.

The subsidiary company entered into an agreement with an association which is a shareholder, to lease land for the construction of a hospital for a period of 30 years, commencing 1 September 1993, with options to renew.

Paolo Medic Co., Ltd.

The subsidiary company entered into a land and premises rental agreement which will be expired in January 2037, and the rental fee is paid on a monthly basis at the amount as stipulated in the agreement.

Phyathai 1 Hospital Co., Ltd.

The subsidiary company entered into a land rental agreement with a state enterprise for a period of 3 years expiring in the year 2013 and made an additional memorandum of renewal the land rental agreement for another 3 years expiring in the year 2016. The subsidiary company will pay rental fee as stipulated in the memorandum.

Sriracha Nakorn General Hospital Public Co., Ltd.

The subsidiary company entered into a land rental agreement with the Treasury Department and the rental fee is paid on monthly basis as stipulated in the agreement.

36. Commitments and contingent liabilities

As at 31 December 2015 and 2014, commitments and contingent liabilities are as follows:

	(Unit: Million Baht)					
	As at 31 December 2015					
	Consolidated financial statements			Separate financial statements		
	Within 1 year	1 -5 years	Over 5 years	Within 1 year	1 -5 years	Over 5 years
Contractual commitments						
- the land and building rental contracts						
(including long-term agreements in Note 35)	220	322	781	22	44	111
- the office equipment rental and other services	317	69	-	173	8	-
- the medical equipment provision and maintenance contracts	200	187	-	118	-	-
- the building construction and decoration contracts	1,333	-	-	119	-	-
- the sale and purchase contract for land	124	-	-	-	-	-
Total	<u>2,194</u>	<u>578</u>	<u>781</u>	<u>432</u>	<u>52</u>	<u>111</u>
	(Unit: Million Baht)					
	As at 31 December 2014					
	Consolidated financial statements			Separate financial statements		
	Within 1 year	1 -5 years	Over 5 years	Within 1 year	1 -5 years	Over 5 years
Contractual commitments						
- the land and building rental contracts						
(including long-term agreements in Note 35)	143	318	1,108	40	106	385
- the office equipment rental and other services	271	74	-	181	1	-
- the medical equipment provision and maintenance contracts	279	114	-	114	-	-
- the building construction and decoration contracts	1,382	22	-	112	-	-
- the sale and purchase contract for land	58	-	-	-	-	-
Total	<u>2,133</u>	<u>528</u>	<u>1,108</u>	<u>447</u>	<u>107</u>	<u>385</u>

Contingent liabilities

As at 31 December 2015, the Company and its subsidiaries had outstanding bank guarantees of approximately Baht 606 million (2014: Baht 291 million) and the Company's was Baht 335 million (2014: Baht 36 million) issued by the bank on behalf of the Company and its subsidiaries in respect of certain performance bonds as required in the normal course of business, such as facility usage and contractual performance.

A subsidiary company has guaranteed credit facility with a financial institution amounting to Baht 3.9 million for a former associated company. Currently, it is in the processing of cancellation this guarantee for credit facility.

37. Segment information

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance. The chief operating decision maker has been identified as the executive committee.

The Company and its subsidiaries have two reportable segments that are hospital operations and other businesses that support hospital business including central lab, manufacturer and distributor of medicine and pharmaceutical products, assets management for healthcare business, restaurant and distribution of health food products and facility management, accounting services, technology and information service, training business, health insurance and life insurance broker. These two segments have similar economic characteristics. They both have common customer group, similar service provision methods and similar management.

In addition, the operations of the Company and its subsidiaries are carried on in the geographical areas of Thailand and overseas.

As hospital operation is the main business segment and the segment information that has been considered based on a quantitative basis is over 90 percent of the total population both operational and geographical areas. For this reason, the management considers to aggregate operating segments into one operating segment of hospital operation. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical areas.

For the years 2015 and 2014, the Company and its subsidiaries has no major customer with revenue of 10 percent or more of its revenues.

38. Promotional privileges

The Company has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 2302(2)/2553, dated 26 November 2010, for hospital business Type 7.7. Significant privileges are as follows:

- Exemption of import duty on machinery as approved by the board.
- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 8 years commencing from the date that revenues are first derived from the promoted operation (commencing from 2010 and will be expired in 2018).

In case of losses being incurred during the corporate income tax exemption period, the Company is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period (from 2018 to 2023), whether from any one year or from several years.

- Exemption from income tax on dividend paid from the profit of the promoted operations throughout the tax exemption period.

A.N.B. Laboratories Co., Ltd.

A.N.B. Laboratories Co., Ltd. has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 1913(2)/2554, dated 4 August 2011, for production of large-volume of sterile solution (saline solution), promotional certificate No. 1163(2)/2558, dated 6 February 2015, for production of injectable contraceptives and promotional certificate No. 1309(2)/2558, dated 13 March 2015, for production of small-volume of sterile solution, type 6.5 for production of pharmaceuticals and/or pharmaceutical active ingredients. Significant privileges are as follows:

- Exemption of import duty on machinery as approved by the board.
- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 5 years commencing from the date that revenues are first derived from the promoted operation (commencing from 2011 and will be expired in 2016 and commencing from 2015 and will be expired in 2020, respectively).

In case of losses being incurred during the corporate income tax exemption period, the subsidiary is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period (from 2016 to 2021 and from 2020 to 2025, respectively), whether from any one year or from several years.

- Exemption from income tax on dividend paid from the profit of the promoted operation throughout the tax exemption period.

The Medicpharma Co., Ltd.

The Medicpharma Co., Ltd. has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 1218(2)/2553, dated 3 March 2010, for production of medicines for human use, type 6.5 for production of pharmaceuticals and/or pharmaceutical active ingredients from 25 January 2010 and promotional certificate No. 1778(2)/2558, dated 22 June 2015, for production of modern medicines for human and animal use, type 6.5 for production of pharmaceuticals and/or pharmaceuticals active ingredients. Significant privileges are as follows:

- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 5 years commencing from the date that revenues are first derived from the promoted operation (commencing from 2010 and will be expired in 2015 and commencing from 2016 and will be expired in 2021, respectively).
- Revenues that must be included in calculation of net profit is revenue from sales of by products such as scrap or waste from production process.
- In case of losses being incurred during the corporate income tax exemption period, the subsidiary is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period (from 2015 to 2020 and from 2021 to 2026, respectively), whether from any one year or from several years.
- Exemption from income tax on dividend paid from the profit of the promoted operation throughout the tax exemption period.

Bangkok Helicopter Services Co., Ltd.

Bangkok Helicopter Services Co., Ltd. has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 1709(2)/2550, dated 20 June 2007. Significant privileges are as follows:

- Exemption of import duty on machinery as approved by the board.
- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 8 years commencing from the date that revenues are first derived from the promoted operation.
- In case of losses being incurred during the corporate income tax exemption period, the subsidiary is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period (from 2014 to 2019), whether from any one year or from several years.
- Exemption from income tax on dividend paid from the profit of the promoted operation throughout the tax exemption period, in accordance with the section 31.

As the subsidiary was unable to achieve ISO 9000 certification or other equivalent international standard certifications within 2 years from the first day of its operation as required by Investment promotion certificate No. 9, the period for privilege relating to corporate income tax of the subsidiary was reduced by 1 year to 7 years. The said privilege expired on 11 December 2014.

National Healthcare Systems Co., Ltd.

National Healthcare Systems Co., Ltd. has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 2071(4)/2557, dated 3 September 2014, for scientific laboratories, type 7.21 for service of scientific laboratories from 15 July 2014. Significant privileges are as follows:

- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 8 years commencing from the date that revenues are first derived from the promoted operation (commencing from 2015 and will be expired in 2023).

- In case of losses being incurred during the corporate income tax exemption period, the Company is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period (from 2023 to 2028), whether from any one year or from several years.
- Exemption from income tax on dividend paid from the profit of the promoted operation throughout the tax exemption period.

N Health Pathology Co., Ltd.

N Health Pathology Co., Ltd. has been granted promotional privileges under The Investment Promotion Act B.E. 2520, according to the promotional certificate No. 58-2021-1-00-2-0, dated 11 August 2015, for scientific laboratories, type 7.14 for service of scientific laboratories from 29 June 2015. Significant privileges are as follows:

- Exemption from corporate income tax derived from the promoted operation, with the limited rate of 100 percent of the investment excluding land and working capital for a period of 8 years commencing from the date that revenues are first derived from the promoted operation.
- In case of losses being incurred during the corporate income tax exemption period, the subsidiary is allowed to utilise the loss as a deduction against net profits for a period of 5 years after exemption period, whether from any one year or from several years.
- Exemption from income tax on dividend paid from the profit of the promoted operation throughout the tax exemption period.

As at 31 December 2015 the subsidiary has no revenue from service of scientific laboratories that entitled to the promotional privileges.

The Company and its subsidiaries must comply with the conditions stipulated in the investment promotional privileges.

Revenues of the Company and its subsidiaries for the years 2015 and 2014 can be separated between the promoted and non-promoted operation as follows:

(Unit: Thousand Baht)

	Consolidated financial statements					
	Promoted operation		Non-promoted operation		Total	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
		(Restated)		(Restated)		(Restated)
Revenue from hospital operations	651,532	588,611	59,610,832	53,752,739	60,262,364	54,341,350
Other income	957,757	1,205,720	2,709,232	1,446,814	3,666,989	2,652,534
Total revenues	<u>1,609,289</u>	<u>1,794,331</u>	<u>62,320,064</u>	<u>55,199,553</u>	<u>63,929,353</u>	<u>56,993,884</u>

(Unit: Thousand Baht)

	Separate financial statements					
	Promoted operation		Non-promoted operation		Total	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Revenue from hospital operations	639,185	588,611	12,459,488	11,164,738	13,098,673	11,753,349
Other income	-	-	4,607,577	3,540,803	4,607,577	3,540,803
Total revenues	<u>639,185</u>	<u>588,611</u>	<u>17,067,065</u>	<u>14,705,541</u>	<u>17,706,250</u>	<u>15,294,152</u>

39. Fair value hierarchy

As at 31 December 2015, the Company and its subsidiaries had the assets and liabilities that were measured at fair value using different levels of inputs as follows:

(Unit: Million Baht)

	Consolidated Financial Statements			
	Level 1	Level 2	Level 3	Total
Assets measured at fair value				
Mutual funds	0.8	-	-	0.8
Available-for-sale investments				
Equity instruments	893	-	-	893
Investment property	-	36	249	285
Land	-	18,658	-	18,658
Land not used in operations	-	297	-	297

(Unit: Million Baht)

	Consolidated Financial Statements			
	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value				
Investments in associated companies	46,070	-	-	46,070
Derivative				
Selling forward exchange contracts	-	0.2	-	0.2
Liabilities for which fair value are disclosed				
Derivatives				
Buying forward exchange contracts	-	0.2	-	0.2
Interest rate swap	-	36	-	36
Debentures	-	11,344	-	11,344
Convertible debentures	10,877	-	-	10,877

(Unit: Million Baht)

	Separate Financial Statements			
	Level 1	Level 2	Level 3	Total
Assets measured at fair value				
Mutual funds	0.8	-	-	0.8
Available-for-sale investments				
Equity instruments	762	-	-	762
Investment property	-	289	241	530
Land	-	2,571	-	2,571
Land not used in operations	-	297	-	297
Financial assets measured at fair value				
Investments in associated companies	46,070	-	-	46,070
Liabilities for which fair value are disclosed				
Derivatives				
Buying forward exchange contracts	-	0.2	-	0.2
Interest rate swap	-	36	-	36
Debentures	-	11,344	-	11,344
Convertible debentures	10,877	-	-	10,877

40. Financial instruments

40.1 Financial risk management

The Company and its subsidiaries' financial instruments, which are defined under Thai Accounting Standard No. 107 "Financial Instruments: Disclosure and Presentation", principally comprise the financial assets and liabilities mentioned in Note 5.21 to financial statements. The Company and its subsidiaries have the financial risks associated with these financial instruments and how they are managed is described below.

Credit risk

The Company and its subsidiaries are exposed to credit risk primarily with respect to trade, loans and other receivables. The Company and its subsidiaries manage the risk by adopting appropriate credit control policies and procedures, therefore does not expect to incur material financial losses. In addition, the Company and its subsidiaries do not have high concentration of credit risk since it has a large customer base. The maximum exposure to credit risk is limited to the carrying amounts of trade, loans and other receivables as stated in the statement of financial position.

Interest rate risk

The Company and its subsidiaries are exposed to interest rate risk relates primarily to its cash at banks, bank overdrafts, short-term loans, long-term loans, and debentures. However, most of financial assets and liabilities bear floating interest rates or fixed interest rates which are close to the market rate and the Company enters into interest rate swap contract to manage this risk as appropriate.

Interest rate swap contract

Interest rate swap contract is entered into to manage exposure to fluctuations in interest rate.

On 4 April 2014, the Company entered into a nine-year interest rate swap contract with a financial institution by converting the interest rate of fixed rate per annum to fixed rate for the first 4 years and floating rate based on Fixed Deposit Rate plus fixed rate per annum for the last 5 years on the debentures balance as described in Note 26. Then, on 15 October 2014, the Company agreed with the financial institution to change interest rate whereby they agreed to reduce the interest rate in the first year and to change the interest rate from floating rate in the fifth and the sixth year to a fixed rate, with the interest rate of other years maintained as same as specified in the contract.

On 17 June 2015, the Company entered into a ten-year interest rate swap contract with a financial institution by converting the interest rate of fixed rate per annum to floating rate based on 3-month BIBOR minus the fixed rate per annum on the debentures balance as described in Note 26.

Net fair value

The net fair value of interest rate swap contract at the statements of financial position date was:

	Consolidated		(Unit: Million Baht)	
	financial statements		Separate	
	2015	2014	2015	2014
Fair value of interest rate swap contract - asset	35.9	70.6	35.9	70.6

Fair value of interest rate swap contract has been calculated using rate quoted by the financial institution as if the contract was terminated at the statements of financial position date.

Significant financial assets and liabilities classified by type of interest rate are as follows:

	(Unit: Million Baht)					
	As at 31 December 2015					
	Consolidated financial statements					
	Fixed interest rates			Floating interest rate	Non-interest bearing	Total
	Within 1 year	1-5 years	Over 5 years			
Financial Assets						
- Cash and cash equivalent	500	-	-	5,001	28	5,529
- Short-term investments	28	-	-	-	-	28
- Trade and other accounts receivable	-	-	-	-	6,484	6,484
- Restricted financial institution deposit	53	-	-	8	-	61
- Investments	-	-	-	-	16,178	16,178
	581	-	-	5,009	22,690	28,280
Financial liabilities						
- Bank overdrafts and short-term loans from financial institution	-	-	-	76	-	76
- Trade and other payables	-	-	-	-	4,935	4,935
- Short-term loans	98	-	-	-	-	98
- Long-term loans	-	2,500	-	6,946	-	9,446
- Liabilities under finance lease agreements	57	47	-	-	-	104
- Debentures	1,000	1,999	7,592	-	-	10,591
- Convertible debentures	-	9,683	-	-	-	9,683
	1,155	14,229	7,592	7,022	4,935	34,933

(Unit: Million Baht)

As at 31 December 2014

Consolidated financial statements

	Fixed interest rates			Floating interest rate	Non-interest bearing	Total
	Within 1 year	1-5 years	Over 5 years			
Financial Assets						
- Cash and cash equivalent	23	-	-	3,563	22	3,608
- Short-term investments	295	-	-	-	1,583	1,878
- Trade and other accounts receivable	-	-	-	-	5,822	5,822
- Restricted financial institution deposit	25	-	-	5	-	30
- Investments	-	-	-	-	15,190	15,190
	<u>343</u>	<u>-</u>	<u>-</u>	<u>3,568</u>	<u>22,617</u>	<u>26,528</u>
Financial liabilities						
- Bank overdrafts and short-term loans from financial institution	-	-	-	22	-	22
- Trade and other payables	-	-	-	-	4,389	4,389
- Short-term loans	89	-	-	-	-	89
- Long-term loans	32	2,530	-	8,402	-	10,964
- Liabilities under finance lease agreements	59	101	-	-	-	160
- Debentures	2,500	999	7,593	-	-	11,092
- Convertible debentures	-	9,346	-	-	-	9,346
	<u>2,680</u>	<u>12,976</u>	<u>7,593</u>	<u>8,424</u>	<u>4,389</u>	<u>36,062</u>

(Unit: Million Baht)

As at 31 December 2015

Separate financial statements

	Fixed interest rates			Floating interest rate	Non-interest bearing	Total
	Within 1 year	1-5 years	Over 5 years			
Financial Assets						
- Cash and cash equivalent	-	-	-	3,612	5	3,617
- Short-term investments	1	-	-	-	-	1
- Trade and other receivables	-	-	-	-	1,470	1,470
- Short-term loans to related parties	-	-	-	1,327	-	1,327
- Restricted financial institution deposit	14	-	-	-	-	14
- Long-term loans to related parties	-	-	-	5,786	-	5,786
- Investments	-	-	-	-	48,871	48,871
	<u>15</u>	<u>-</u>	<u>-</u>	<u>10,725</u>	<u>50,346</u>	<u>61,086</u>
Financial liabilities						
- Trade and other payables	-	-	-	-	1,289	1,289
- Short-term loans from related parties	-	-	-	8,303	-	8,303
- Long-term loans	-	2,500	-	6,870	-	9,370
- Liabilities under finance lease agreements	10	7	-	-	-	17
- Debentures	1,000	1,999	7,592	-	-	10,591
- Convertible debentures	-	9,683	-	-	-	9,683
	<u>1,010</u>	<u>14,189</u>	<u>7,592</u>	<u>15,173</u>	<u>1,289</u>	<u>39,253</u>

(Unit: Million Baht)

	As at 31 December 2014					
	Separate financial statements					
	Fixed interest rates			Floating	Non-	
	Within 1		Over 5	interest	interest	
	year	1-5 years	years	rate	bearing	Total
Financial Assets						
- Cash and cash equivalent	-	-	-	1,859	4	1,863
- Short-term investments	1,583	-	-	-	-	1,583
- Trade and other receivables	-	-	-	-	1,052	1,052
- Short-term loans to related parties	-	-	-	1,756	-	1,756
- Restricted financial institution deposit	14	-	-	-	-	14
- Long-term loans to related parties	-	-	-	5,341	-	5,341
- Investments	-	-	-	-	46,250	46,250
	1,597	-	-	8,956	47,306	57,859
Financial liabilities						
- Trade and other payables	-	-	-	-	928	928
- Short-term loans from related parties	-	-	-	4,703	-	4,703
- Long-term loans	-	2,500	-	8,345	-	10,845
- Liabilities under finance lease agreements	11	15	-	-	-	26
- Debentures	2,500	999	7,593	-	-	11,092
- Convertible debentures	-	9,346	-	-	-	9,346
	2,511	12,860	7,593	13,048	928	36,940

Foreign currency risk

The Company and its subsidiaries are exposed to foreign currency risk mainly in respect of purchase of medical tools and equipment and sales of goods transactions which are denominated in foreign currencies. A subsidiary company seeks to manage this risk by entering into forward exchange contracts. Generally, the forward contracts mature within one year.

Forward exchange contract

As at 31 December 2015 and 2014, a subsidiary company has the outstanding balance of selling forward exchange contracts as follows:

Balance as at	Foreign currency	Amount sold	Contractual exchange rate for amount sold
			(Baht per foreign currency unit)
31 December 2015	US Dollar	756,315	35.76 - 36.22
31 December 2014	US Dollar	969,981	32.60 - 33.24

As at 31 December 2015 and 2014, the Company has the outstanding balance of buying forward exchange contracts as follows:

Balance as at	Foreign currency	Amount bought	Contractual exchange rate for amount bought (Baht per foreign currency unit)
31 December 2015	US Dollar	237,961	33.96 - 35.51
31 December 2014	US Dollar	-	-

Net fair value

Selling forward exchange contract

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Fair value of selling forward exchange contract (liabilities)	(205.5)	(229.1)	-	-

Buying forward exchange contract

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Fair value of buying forward exchange contract - assets	230.3	-	230.3	-

Fair value of forward exchange contract has been calculated using rate quoted by the financial institution as if the contracts were terminated at the statements of financial position date.

40.2 Fair values of financial instruments

Since the majority of the Company and its subsidiaries' financial instruments bear floating interest rates or fixed interest rates which are close to market rate, their fair value is not expected to be materially different from the amounts presented in the statement of financial position.

41. Capital management

The primary objective of the Company's and its subsidiaries' capital management is to ensure that they have appropriate capital structure in order to support its business and maximise shareholders value. As at 31 December 2015, the Group's debt-to-equity ratio was 0.8:1.0 (2014: 0.9:1.0) and the Company's was 1.4:1.0 (2014: 1.4:1.0).

42. Subsequent events after reporting date

Referring to Board of Directors of the Company's Meeting number 2/2016 held on 29 February 2016, has resolution to establish a new subsidiary company, the objective is to manage the asset of the Group which is not directly relevant to hospital operation. The new company has registered capital of Baht 10 million and is wholly owned by the Company.

43. Approval of financial statements

These financial statements have been authorised for issue by the Company's Board of Directors on 29 February 2016.